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Evidence supports potential short-term benefits of integrative healthcare (IH) for cancer patients, 
which combines conventional Western medicine with adjunctive, complementary treatments; 
however, the long-term efficacy of IH has not been systematically studied. The current study 
examined the short- and long-term effectiveness of IH for cancer patients, relative to treatment as 
usual (TAU), in improving emotional and immune health. Also examined were systematic 
differences at baseline (i.e., emotional distress, sociodemographic and cancer variables) 
associated with IH usage. Patients were recruited from a University Medical Center (n = 178) 
and were eligible to participate irrespective of cancer diagnosis and stage. Patients opted to 
continue TAU or engage in an IH program. Patients were assessed at three intervals (baseline, 3-
month and 12-month follow-up). A subset of the sample (29%; n = 52) was randomized to a 
blood draw condition. Forty percent of the sample utilized IH services between baseline and 12-
month follow-up. Logistic regression analyses revealed patients utilizing IH services (0 = no 
usage; 1 = 1+ times) presented with higher baseline depression and anxiety. Improvements in 
health-related quality of life (HRQOL) were evidenced at T2 for IH participants, but were not 
maintained at T3. Exploratory analyses at T2 revealed psychotherapy contributes to greater 
reductions in depression and anxiety scores, relative to other services (i.e., massage and 
acupuncture). Overall, findings offer preliminary but limited support for short-term benefits of 
IH in improving HRQOL and suggest that integrating psychotherapy and IH may be worth 
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Depression has been consistently linked to poorer outcomes for cancer patients, and 
treatment outcome studies have begun to explore the effectiveness of psychosocial interventions 
for cancer patients, with neuroendocrine and immune mechanisms proposed as potential 
mechanisms of change for these interventions (Subnis, Starkweather, McCain, & Brown, 2014).  
The study of these relations in complementary and alternative medicine (CAM) modalities of 
care for cancer patients is relatively limited, with evidence emerging to suggest the short-term 
effectiveness of these adjunctive treatments (Baker et al., 2012; Helyer et al., 2006) but lacking 
in regards to the long-term efficacy of such treatment programs (Barnett & Shale, 2012). This 
study constitutes a pilot study that aims to determine the long-term effectiveness (i.e., baseline to 
one-year follow-up) of an integrative healthcare program in improving outcomes for cancer 
patients, as well as factors associated with integrative healthcare usage in cancer patients across 
the cancer care continuum. 
Depression and inflammation 
  Depression is the most common psychiatric disorder among cancer patients, with 
prevalence rates ranging from 10-50% and the highest rates occurring among those diagnosed 
with pancreatic, oropharyngeal, breast, and lung cancers (Massie, 2004; McDaniel, Musselman, 
& Nemeroff, 1997; Miller, Ancoli-Israel, Bower, Capuron, & Irwin, 2008). Depression can be as 
debilitating as the physical effects of cancer and negatively affects treatment adherence and 
quality of life (Knopf & Head, 2012; Miller et al., 2008). Moreover, depression is thought to be 
independently predictive of cancer outcomes, including mortality or low survival rates (Lloyd-
Williams, Shiels, Taylor, & Dennis, 2009; Pinquart & Duberstein, 2010; Satin, Linden, & 
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Philips, 2009). A meta-analysis conducted by Satin et al. (2009) found increased mortality rates 
among depressed cancer patients, such that mortality was up to 29% higher in patients endorsing 
depressive symptoms and up to 39% higher among those with a diagnosis of clinical depression, 
highlighting the detrimental effects of depression on outcomes, particularly if left unaddressed or 
untreated.  
Research strongly supports the notion that cancer patients experience significant cancer-
related distress, depression, anxiety, and stress (Croyle & Rowland, 2003; Fann et al., 2008; 
Massie, 2004), in the first year following their cancer diagnosis (Burgess et al., 2005; Rowland, 
1999) and throughout the course of treatment into long-term survivorship (Stanton, Rowland, & 
Ganz, 2015). Functional impairment is also evident in many cancer patients in several areas, 
including poorer physical health, increased substance use, and reduced quality of life in areas 
such as physical/recreational activities, sleep, self-care, interpersonal relationships, and sexual 
functioning (Burgess et al., 2005; Ciaramella & Poli, 2001; Evans et al., 2005; Fortner, 
Stepanski, Wang, Kasprowicz, & Durrence, 2002; Lundberg & Passik, 1997). Evidence is 
accumulating to suggest that depressed and anxious cancer patients experience decreased 
immune system functioning, more rapid progression of cancer, increased pain, and possibly 
increased mortality relative to non-depressed patients (Ciaramella & Poli, 2001; Glover et al., 
1995; Reddick, Nanda, Campbell, Ryman, & Gaston-Johansson, 2005; Pinquart & Duberstein, 
2010; Spiegel & Giese-Davis, 2003). Several pathophysiological mechanisms are thought to 
underlie the relationship between depression and cancer outcomes, including survival rates, with 
one of the primary mechanisms of focus being depressogenic effects on cellular immunity.  
The close association between cancer and depression is due, in part, to the activation of 
immuno-inflammatory systems and dysregulation of the hypothalamic-pituitary-adrenal (HPA) 
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axis (Belmaker & Agam, 2008; Lutgendorf, Sood, & Antoni, 2010). More specifically, 
depression is thought to down-regulate or impair the immune system, largely via adrenergic and 
glucocorticoid signaling pathways, and is associated with increased pro-inflammatory cytokine 
production (Lutgendorf et al., 2010; Miller, Maletic, & Raison, 2009). The stimulation of pro-
inflammatory cytokines is a stress response secondary to and triggered by activation of the 
autonomic nervous system and HPA axis (Lutgendorf et al., 2010), and chronically high levels of 
circulating pro-inflammatory cytokines have been linked to severe depression (Howren, Lamkin, 
& Suls, 2009; Raison, Capuron, & Miller, 2006). Depression appears to promote tumor 
recurrence and progression by suppressing immunity and altering the balance of pro-
inflammatory (T-helper 1; TH1) to anti-inflammatory (T-helper 2; TH2) cytokines. This cytokine 
imbalance creates a tumor microenvironment favoring immunosuppression, angiogenesis 
(development of tumor vasculature), and cancer cell growth (Lutgendorf et al., 2010; Miller et 
al., 2009).  
In particular, interleukin-6 (IL-6), a pro-inflammatory (TH1) cytokine that acts in 
synergy with other signaling proteins (e.g., IL-1 and tumor necrosis factor-alpha [TNF-α]), is 
regarded as an especially important prognostic indicator in cancer patients (Howren et al., 2009; 
Musselman et al., 2001). IL-6 is one of the most dysregulated cytokines in cancer patients, with 
high levels predictive of mortality (Seruga, Zhang, Bernstein, & Tannock, 2008) and 
demonstrating involvement in angiogenesis (Lutgendorf et al., 2010). Clinically depressed 
cancer patients have significantly higher levels of IL-6 than non-depressed cancer patients and 
healthy controls (Musselman et al., 2001; Seruga et al., 2008). However, there is relatively 
limited research comparing cytokine levels in depressed and non-depressed cancer patients to 
other medically ill populations and healthy controls (Miller et al., 2008), and longitudinal 
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research examining and more clearly delineating cytokine profiles of these groups throughout 
treatment and across various disease types and stages is greatly needed.  
Howren, Lamkin, & Suls (2009) conducted a quantitative review of the literature that 
showed IL-6, C-reactive protein (CRP), and IL-1 (to a lesser extent), as positively associated 
with depression in both clinic- and community-based samples. IL-6 and IL-1 are precursors to 
CRP, stimulating its production in the liver through the activation of enzymes (Heikkila, 
Ebrahim, Rumley, Lowe, & Lawlor, 2007). CRP is a non-specific protein and highly sensitive 
marker of systemic inflammation that has been consistently linked to increased risk for cardiac 
disease (Howren et al., 2009) and has only recently begun to be explored in relation to cancer 
outcomes (Heikkila et al., 2007). A study by Heikkila et al. (2007) found elevated levels of 
circulating CRP and IL-6 to be associated with increased mortality in elderly women with and 
without cancer, suggesting that these biomarkers may be related to more general comorbidities 
(e.g., lifestyle, sociodemographic factors, etc.) than to cancer malignancy specifically. In a recent 
meta-analysis, CRP was found to correlate more strongly with depression, as compared to IL-6, 
and was theorized to represent more broadly the cumulative effects of a range of inflammatory 
proteins (Valkanova, Ebmeier, & Allen, 2013). Although relatively few studies have examined 
CRP and IL-6 simultaneously in the same sample, both of these inflammatory markers are 
strongly associated with one another (Valkanova et al., 2013), with IL-6 having an established 
relation to immune functioning in cancer populations (Musselman et al., 2001), despite its lower 
association with depression across broader community-based samples. As such, studying these 
biomarkers (CRP and IL-6) in conjunction in the same sample may serve to capture broader and 
more specific effects on inflammatory processes.  
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Inflammation is regarded as a key biological mechanism in physical health decline in 
general and is considered a prognostic indicator of a host of systemic diseases and chronic 
illnesses (Kiecolt-Glaser, 2010; Miller et al., 2008). It is important to note that inflammation 
itself is known to produce “sickness behavior” (e.g., pain, fatigue, sleep disturbance) and other 
behavioral alterations in healthy individuals, cancer patients, and other medically ill patients 
alike (Ahles & Saykin, 2007; Cleeland, Bennett, & Dantzer, 2003), indicating a complex, 
bidirectional relationship between inflammation and depression. This bi-directionality is widely 
acknowledged and is such that: depression triggers inflammatory responses and inflammation 
triggers behavioral change and depressive symptoms, also referred to as inflammation-based 
depression (Kiecolt-Glaser, Derry, & Fagundes, 2015; Miller et al., 2008). Both increased pro-
inflammatory (TH1) cytokine production and depression severity have been linked to multiple 
behavioral comorbidities and negative consequences for cancer patients, including increased 
pain, fatigue, cognitive impairment, drug toxicity and resistance, and tumor malignancy 
(Lutgendorf et al., 2010; Seruga et al., 2008; Spiegel & Giese-Davis, 2003). Depression itself is 
associated and often comorbid with a host of health-risk behaviors, such as sleep and appetite 
disturbances, reduced physical activity (i.e., behavioral deactivation), increased alcohol use, and 
smoking, all of which have been linked to increased inflammation (Kiecolt-Glaser et al., 2015). 
For example, sedentary behavior, sleep loss, and diets high in saturated fats have been associated 
with high levels of circulating pro-inflammatory cytokines (e.g., CRP and Interleukin-6), 
whereas healthier behaviors (e.g., increased exercise, diets high in fruits and vegetables, and 
moderate alcohol intake) have been associated with lower levels of inflammatory biomarkers 
(Kiecolt-Glaser et al., 2015; O’Connor et al., 2009). 
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In addition, cancer treatment (e.g., chemotherapy, radiation, immunotherapy, hormone 
therapy, surgery, etc.) activates an immune response and alters the tumor microenvironment, 
stimulating the production of pro-inflammatory cytokines and producing toxic treatment effects 
and behavioral comorbidities, such as nausea, fatigue, and depressed mood (Bower et al., 2011; 
Miller et al., 2008; Seruga et al., 2008; Sridharan & Schoenfeld, 2015). For example, interferon 
(IFN)-alpha treatment is associated with a high rate of depression, with 30-45% of patients 
receiving IFN-alpha being diagnosed with depression during the course of immunotherapy 
(Capuron & Miller, 2004). IFN-alpha is a cytokine with anti-viral properties often delivered as a 
treatment for cancer and infectious diseases, which effectively highlights another mechanism by 
which cytokines may induce depression and behavioral changes – specifically, via effects on 
regional brain activity (Miller et al., 2008). IFN-alpha has been shown to increase blood flow in 
the dorsal region of the anterior cingulate cortex (dACC), a brain region thought to play an 
important role in vigilance, with increased activity in this region associated with elevated risk for 
anxiety and mood disorders ((Miller et al., 2008). Cytokines, such as IL-6 and IFN-alpha, are 
also thought to affect the synthesis and reuptake of neurotransmitters, such as serotonin, known 
to play a role in the development of depression (Miller et al., 2008).  
In summary, complex bidirectional relationships exist between inflammation and 
depression, such that elevations in pro-inflammatory cytokines trigger depressive symptoms, and 
vice versa (i.e., depression increases pro-inflammatory cytokine production), and each induces 
behavioral changes, or “sickness behaviors” (e.g., behavioral deactivation, appetite disturbance), 
that in turn cycle back and exert effects on mood and inflammation. There exists a complex 
constellation of neuroendocrine and immune mechanisms involved in the development and 
maintenance of depression. For cancer patients, this constellation of interactions is further 
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complicated by the fact that cancer treatment itself induces inflammation, and thereby 
depression. Whereas cytokine antagonists, antidepressants, and other anti-inflammatory agents 
are often employed to curb depressive and other behavioral symptoms (Cleeland et al., 2003; 
Miller et al., 2008), research on behavioral interventions and its effect on neuroendocrine-
immune functioning in cancer patients is in its infancy (Subnis et al., 2011). Although 
pharmacological interventions are often employed to reduce circulating cytokines in clinically 
depressed patients (Croyle & Rowland, 2003), pharmacological treatment is generally less 
effective if psychosocial support is not provided (Knopf & Head, 2012). 
Psychosocial interventions  
Given the prevalence and impact of depression, anxiety, and chronic stress in cancer 
patients, the importance of developing and evaluating psychosocial interventions for this 
population has been highlighted as a pressing need (Fann et al., 2008; Spiegel & Giese-Davis, 
2003). The field of behavioral health is poised to make a meaningful contribution to cancer care 
and mortality via interventions aimed at treating and ameliorating depression, anxiety, and 
overall emotional distress in this population. In fact, the Institute of Medicine (IOM) indicated 
psychosocial therapies as essential for patients across the cancer care continuum, including 
patients of all cancer types and stages, such as late-stage cancers and cancer survivors (Adler & 
Page, 2008). 
There is substantial evidence for the efficacy of psychotherapy in alleviating depression, 
anxiety, and cancer-specific distress (Costanzo et al., 2011), with multiple meta-analyses 
confirming the benefits of psychotherapeutic interventions for cancer patients (DiStasio, 2008; 
Lepore & Coyne, 2006; Lin et al., 2011; Meyer & Mark, 1995; Newell, Sanson-Fisher, & 
Savolainen, 2002; Sheard & Maguire, 1999; Williams & Dale, 2006). Many studies have found 
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behavioral interventions, delivered in individual and group formats, to be effective in reducing 
distress and symptoms of depression, anxiety, pain, and cancer-related fatigue and in improving 
quality of life and social functioning in cancer patients (Fann et al., 2008; Goodwin et al., 2001; 
Kissane et al., 2007; Moorey, Greer, Bliss, & Law, 1998; Rehse & Pukrop, 2003; Stanton et al., 
2015; Williams & Dale, 2006). However, there also are studies where psychosocial interventions 
have had only minimal or mixed effects in reducing distress and improving outcomes, such as 
survival rates, for cancer patients (Antoni et al., 2013; Cunningham et al., 1998; Goodwin et al., 
2001; Kissane et al., 2007; Coyne, Lepore, & Palmer, 2006; Mustafa, Carson-Stevens, Gillespie, 
& Edwards, 2013).  
Given the mixed results of treatment outcome studies, at present the general consensus is 
that some psychosocial interventions, such as cognitive-behavioral therapy, mindfulness-based 
stress reduction, behavioral activation, problem-solving therapy, and supportive-expressive 
group therapy, may be effective in reducing depression and anxiety in cancer patients (Fann et 
al., 2008; Hopko et al., 2011; Hopko, Lejuez, Ryba, Shorter, & Bell, 2016; Williams & Dale, 
2006; Newell et al., 2002). However, significant methodological limitations have been indicated 
in treatment outcome research with cancer patients, including small sample sizes and relatively 
short follow-up windows (less than 6-months), making it difficult to evaluate the long-term 
effectiveness of many interventions (Newell et al., 2002). Given the limits of treatment outcome 
research to date and the prevalence and impact of emotional health issues in the cancer 
population, studies examining the efficacy of novel treatment approaches for cancer patients are 





Complementary Health Approaches 
Among novel treatments developed to ameliorate the psychosocial impact of cancer is 
integrative healthcare (IH), which combines conventional Western medicine with adjunctive, 
complementary treatments (Deng & Cassileth, 2005a). Within the past two decades, there has 
been a growing interest among cancer patients and survivors in the use of complementary and 
alternative medicine (CAM) treatments as adjuvants to standard care to reduce the burden and 
stress of cancer diagnosis and treatment (Buettner et al., 2006; Cassileth & Chapman, 1996; 
Fouladbakhsh & Sommel, 2010; Williams & Dale, 2006). CAM is used by up to 80% of cancer 
patients (Deng & Cassileth, 2005b; Helyer et al., 2006), with estimates varying broadly, in part 
due to lacking and varying definitions of CAM (Deng & Cassileth, 2005b). The National Center 
for Complementary and Integrative Health (NCCIH) defines CAM, or “complementary health 
approaches,” as a diverse group of practices and natural products used in conjunction with 
conventional medicine, whereas the term ‘integrative health’ denotes the incorporation of 
complementary approaches into mainstream care (NCCIH, 2016). A recent study found CAM 
usage to be more prevalent among cancer survivors, irrespective of duration of survivorship, as 
compared to the general U.S. population (Fouladbakhsh & Stommel, 2008). While the 
prevalence of CAM services has grown among cancer populations (Fouladbakhsh & Stommel, 
2010; Tindle, Davis, Phillips, & Eisenberg, 2005), factors influencing use have not been 
thoroughly examined (Fouladbakhsh & Stommel, 2008; Yates et al., 2005).  
Gender is known to be a particularly strong determinant of CAM usage in the general 
population in the United States (Barnes, Powell-Griner, McFann, & Nahin, 2004). Women are 
more likely to use CAM services than men, with recent studies suggesting that this trend is 
consistent among cancer, as well as non-cancer, populations (Fouladbakhsh & Stommel, 2008, 
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2010; Yates et al., 2005). Patterns of usage differ slightly by gender, with women having a 
stronger preference for mind-body practices, such as meditation, relaxation, guided imagery, and 
yoga, as compared to men (Fouladbakhsh & Stommel, 2008, 2010). This gender disparity is not 
altogether dissimilar to patterns of use observed in other psychosocial treatment modalities 
(Rehse & Pukrop, 2003), and has been posited as a reflection of the tendency of women to be 
more involved in self-care (Fouladbakhsh & Stommel, 2008, 2010). A similarity among men and 
women in patterns of use appears in their preference for low- or no-cost services (Fouladbakhsh 
& Sommel, 2010).  
There is lesser consensus regarding the influence of other sociodemographic factors (e.g., 
race/ethnicity, age, socioeconomic status, education level, etc.) on CAM usage, when compared 
with the wealth of support for gender as a strong correlate of use (Barnes et al., 2005; 
Fouladbakhsh, Stommel, Given, & Given, 2005).  However, some studies have cited White (non-
Hispanic) individuals and those of younger age, and of higher income and education as the most 
common consumers of CAM services in cancer and non-cancer populations alike (Deng & 
Cassileth, 2005b; Eisenberg et al., 1998; Fouladbakhsh & Stommel, 2008, 2010; Helyer et al., 
2006; Rakovitch et al., 2005; Tindle et al., 2005). With regard to race/ethnicity, a national survey 
of CAM usage in the United States found that Black and Asian adults may be among the highest 
consumers of CAM services in the general population (Barnes et al., 2004). Similarly, some 
studies have not found support for race/ethnicity as a predictor of CAM usage in a cancer 
population (Fouladbakhsh et al., 2005), indicating a need for further exploration in this area.  
Age also appears to have a complex relationship with CAM usage, in that prevalence of 
use peaks in middle age and declines in late-age, in both cancer and non-cancer patients alike 
(Fouladbakhsh and Stommel, 2008, 2010). Estimates of peak age of CAM use for cancer 
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survivors, specifically, have ranged from age 34 (Fouladbakhsh and Stommel, 2008) to age 46 
(Fouladbakhsh and Stommel, 2010), depending upon the sample. Cancer survivors may initiate 
complementary services at younger ages and display less steep declines in usage in late age, as 
compared to the general population (Fouladbakhsh & Stommel, 2008). However, Shen and 
colleagues (2002) found no support for age as a predictor of CAM usage in late-stage breast 
cancer patients, nor was support found for income level or marital status. In their sample, higher 
education remained the only sociodemographic factor associated with increased CAM usage. 
Mixed results have also been found with regard to the predictive power of marital status in 
cancer populations.  Although Shen et al. (2002) did not find support for marital status, other 
studies have suggested that married cancer patients, particularly women, may be more likely to 
use CAM services than those who are single (Helyer, 2006; Wanchai, Armer, & Stewart, 2010). 
By contrast, other studies have suggested that those who are separated or divorced may be more 
inclined to use complementary services (Fouladbakhsh et al., 2005). Another study detected 
similar findings in a sample of cancer survivors, among whom single or widowed individuals 
were more likely to engage in CAM practices (e.g., yoga, meditation, deep breathing), when 
compared to those who were married. In this latter study, marital status was thought to be, in 
part, a reflection of the age distribution of the cancer survivor population, which tended toward 
an older mean age.  
Cancer-specific variables, such as cancer type, cancer stage and treatment, may be 
important determinants of CAM usage (Fouladbakhsh et al., 2005; Yates et al., 2005), with some 
studies beginning to find support, albeit mixed, for this notion. In regards to cancer type, 
research suggests that breast cancer patients may be more likely to use complementary health 
services than patients of other cancer types (Yates et al., 2005; Richardson, Sanders, Palmer, 
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Greisinger, & Singletary, 2000). Alternately, a study of CAM usage across fourteen European 
countries revealed the highest prevalence of use among patients with diagnoses of pancreatic, 
liver, bone/spine, and brain cancer, followed by breast and other cancers (Deng & Cassileth, 
2005b; Molassiotis et al., 2005), whereas other studies have found no effect of cancer type on 
CAM usage (Fouladbakhsh et al., 2005; Fouladbakhsh & Stommel, 2010). With regard to cancer 
stage, there is some evidence to suggest that early-stage cancer patients may engage in CAM 
usage at higher rates when compared to late-stage cancer patients (Fouladbakhsh et al., 2005). 
Relatedly, in cancer survivors, time since diagnosis does not appear to be a significant predictor 
of CAM usage (Fouladbakhsh & Stommel, 2010).  For cancer patients actively in treatment, 
studies suggest treatment type may be relevant to CAM usage. Patients undergoing radiation 
therapy appear least likely to supplement conventional medical care with complementary 
services, whereas patients undergoing cancer surgery, chemotherapy, or a combination of 
chemo-and radiation therapy are more likely to participate in CAM services by comparison 
(Fouladbakhsh et al., 2005; Richardson et al., 2000; Yates et al., 2005).  
Lastly, physical symptoms and emotional distress have been examined as potential 
correlates of CAM usage (Astin, 1998). Pain appears to be a particularly strong somatic/physical 
factor influencing CAM usage in both cancer and non-cancer populations (Astin, 1998; 
Fouladbakhsh & Stommel, 2008), although there have also been mixed results with regard to the 
predictive power of pain and overall perceived health status on CAM usage (Fouladbakhsh et al., 
2005). Mixed effects have also been detected for the predictive value of emotional distress (i.e., 
depression, anxiety) on engagement in complementary health approaches in cancer care (Astin, 
1998; Fouladbakhsh et al., 2005; Fouladbakhsh & Stommel, 2008). Some studies have reported 
anxiety, depression and associated symptoms (e.g., fatigue) as of negligible influence over CAM 
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usage in cancer patients and survivors (Fouladbakhsh & Stommel, 2010; Rakovitch et al., 2005), 
whereas other studies have found an association between the initiation of CAM services and 
indicators of emotional distress (i.e., depression, anxiety, lower quality of life; Burstein, Gelber, 
Guadagnoli, & Weeks, 1999; DiGianni, Garber, Winer, 2002). Despite the higher prevalence of 
pain and depression in a cancer population, as compared to the general population, these factors 
may be no more influential in determining use than in the general (non-cancer) population 
(Fouladbakhsh & Stommel, 2008); in other words, pain and emotional distress may exert a 
significant and comparable influence in cancer and non-cancer populations alike. 
Outcomes associated with CAM usage 
Studies have begun to explore and show preliminary support for CAM services, such as 
yoga, acupuncture, and massage therapy, in reducing depression, anxiety, and distress, and 
improving overall emotional health and quality of life in cancer patients (Banerjee et al., 2007; 
Carlson et al., 2000; Hernandez-Reif et al., 2005; Lin et al., 2011; Oh et al., 2010; Rao et al., 
2008). There is also some evidence, although insufficient in its totality, for the reduction of other 
cancer-related symptoms, such as mental confusion, fatigue, pain, and physical symptoms (e.g., 
hot flashes), following the use of complementary health services and integrative healthcare 
programs (Baker et al., 2012; Bower et al., 2012; Carlson et al., 2000; Chao et al., 2009; Deng & 
Cassileth, 2005a). For example, a recent meta-analysis conducted by Lin et al. (2011) provided 
support for the potential benefits of yoga in improving the emotional health of cancer patients, 
with those using yoga services showing greater improvements in anxiety, depression, distress, 
and overall stress, relative to controls and those in supportive group therapy. Similarly, a pilot 
study on an integrative health intervention offering a wide variety of CAM services (i.e., yoga, 
touch therapies, meditation, art therapy, homeopathy, etc.) to breast cancer patients found that 
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patients using the services were often afforded reduced mental and physical fatigue, breast 
cancer-specific symptoms, and mood disturbance, as well as improved quality of life and 
immune function (Baker et al., 2012). However, some attention has been called to the limited 
data on the utility of CAM modalities for reducing cancer-related fatigue (Lin et al., 2011; Poort 
et al., 2017; Sood et al., 2007) and methodological issues have also been implicated in CAM-
related treatment outcome studies, similar to those indicated for other psychosocial interventions 
(Coyne et al., 2006; Williams & Dale, 2006). Overall, there is some evidence to indicate short-
term benefits of IH usage for cancer patients (Baker et al., 2012; Helyer et al., 2006); however, 
the long-term efficacy of IH has not been systematically studied (Barnett & Shale, 2012).  
A recent meta-analysis conducted by Subnis et al., (2014) examined the effects of 
psychosocial therapies on neuroendocrine-immune functioning in cancer patients, finding the 
highest degree of support for cognitive-behavioral therapy and CAM therapies. The 
complementary health approaches employed in the studies reviewed included: yoga, 
meditation/mind-body skills, massage, and qigong, among others, delivered by a variety of allied 
healthcare professionals.  Of the CAM studies reviewed by Subnis et al. (2014), approximately 
two-thirds (6/9) revealed significant effects on at least one neuroendocrine or immune outcome 
measure. For example, an 8-week group mindfulness-based stress reduction (MBSR) 
intervention, employed with women with early-stage breast cancer and involving breathing 
techniques, meditation, and mindful yoga, was found to improve quality of life, coping (i.e., 
increased use of support systems and optimism) and immune functioning, as measured by 
reductions in cortisol and inflammatory cytokines (IL-4, Il-6, and IL-10), for women who self-
selected into the MBSR group relative to those receiving care as usual (Witek-Janusek et al., 
2008). Similarly, a randomized controlled trial found Medical Qigong, a group mind-body 
 
 15 
intervention with both physical activity and meditation components, to be associated with 
improved quality of life, mood, and cancer-related fatigue and reduced inflammation, as 
measured by serum CRP, in a heterogeneous sample of cancer patients. These findings suggest 
the potential utility of CAM services in boosting immune function in cancer patients, although 
more investigation is needed in this area, with the emerging nature of this data and associated 
methodological issues making it difficult to draw conclusions across studies (Subnis et al., 2014).  
Consistent with treatment outcome studies using exclusively psychosocial data, most 
studies employing neuroendocrine or immune outcomes focus narrowly on breast and prostate 
cancer patients and tend to exclude patients with late-stage cancer or cancer survivors (Adler & 
Page, 2008; Subnis et al., 2014). In their review, Subnis et al. (2014) indicated the need to 
explore the effects of psychosocial treatments on immune outcomes in longitudinal studies with 
varied cancer populations that are more reflective of the cancer care continuum. The lack of 
standardization in biomarkers has made it difficult to make conclusive remarks regarding the 
impact of psychosocial therapies on immune functioning (Subnis et al., 2014); however, this 
issue is not altogether dissimilar to the call for standardized outcome measures in treatment 
outcome studies more generally (Adler & Page, 2008). In summary, while there is some 
evidence to suggest the effectiveness of CAM in alleviating distress and reducing inflammation 
in cancer patients, this body of research is in its relative infancy, and there is a need to explore 
these effects in longitudinal designs that include more heterogeneous samples of cancer patients 







The present study was intended as a pilot study to explore the effectiveness of an 
integrative healthcare program longitudinally and across the cancer care continuum (i.e., all 
cancer types and stages). This Integrative Healthcare (IH) program exists within an academic 
medical center and was designed to provide supportive and integrative therapies for cancer 
patients and their caregivers during all stages of cancer care, beginning from initial diagnosis and 
continuing throughout treatment and into survivorship. This IH program provides access to a 
wide variety of services that include: individual psychotherapy, massage therapy, acupuncture, 
yoga, reiki, and an 8-week mind-body skills course.  
The aims of the current study were two-fold and involved cross-sectional and 
longitudinal analyses of IH usage in a heterogeneous sample of cancer patients. The primary 
aims were as follows: (1) to examine systematic differences between the IH usage and TAU 
group at baseline, in terms of sociodemographic factors (e.g., gender, age, socioeconomic status, 
marital status, etc.), cancer-specific variables (e.g., cancer type, stage, and treatment), and levels 
of emotional distress (i.e., depression, anxiety, etc.); and (2) to evaluate the short-term (3-month) 
and long-term (12-month) effectiveness of an IH program for cancer patients, relative to 
treatment as usual (TAU), in improving emotional and physical/somatic symptoms, quality of 
life, and immune system functioning.  
Aim 1.  Given the lack of consensus regarding socio-demographic and other factors 
influencing cancer patients’ participation in complementary health approaches (Fouladbakhsh et 
al., 2005; Rakovitch et al., 2005; Wanchai et al., 2010), this study aimed to examine systematic 
differences between the IH usage and non-IH usage group, in terms of socio-demographic 
factors, cancer-specific variables, and emotional distress at baseline. 
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Hypothesis 1a. We hypothesized that participants opting in to the IH usage group would 
differ socio-demographically, relative to the TAU group, in terms of age, gender, income level, 
and education, such that those self-selecting into the IH usage group would include a higher 
proportion of females and be, on average, younger and of higher-income and education, when 
compared to the TAU group. Given mixed effects for race/ethnicity and marital status, the 
analyses were exploratory, with no specific direction of effect predicted.  
Hypothesis 1b. We hypothesized that participants opting in to the IH usage group would 
differ in terms of cancer-specific variables, such that those self-selecting into the IH usage group 
would present, on average, with a higher prevalence of breast cancer, when compared to the 
TAU group. Due to mixed effects in the literature for treatment-related variables, analyses for 
treatment type and time since treatment were exploratory, with no specific association predicted.  
Hypothesis 1c. We hypothesized that participants opting in to the IH usage group would 
have more elevated levels of emotional distress at baseline, including higher levels of depression 
and anxiety and lower health-related quality of life, relative to the TAU group. 
Aim 2. Given the need to explore the effectiveness of IH services via longitudinal 
designs (Baker et al., 2012; Helyer et al., 2006) with the inclusion of a broader range of cancer 
patients (Subnis et al., 2014), the current study aimed to examine the short-term and long-term 
efficacy of IH in reducing emotional and physical symptoms and improving immune functioning 
(i.e., IL-6 and CRP) in a heterogeneous sample of cancer patients.  
Hypothesis 2a. We hypothesized that, relative to TAU, participants receiving IH services 
would show greater reductions in depression, anxiety, and somatic/physical symptoms and 
greater improvements in quality of life from baseline to 3-month follow-up (short-term) and 
from baseline to 12-month follow-up (long-term).  
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Hypothesis 2b. We also hypothesized that, relative to TAU, participants receiving IH 
services would show greater improvements in immune health, as measured by CRP and IL-6 for 
a subset of the sample, from baseline to 3-month follow-up (short-term) and from baseline to 12-

























 The present study was intended as a pilot study to examine the short-term and long-term 
effectiveness of an integrative healthcare (IH) program with cancer patients who either opted to 
use complementary treatments as adjuncts to standard care or who opted to receive treatment as 
usual (TAU). This study classifies as an open trial with a single group repeated measures design 
across 12 months. The present study also takes the form of a natural study design in that patients’ 
self-select into the IH program and engage services of their choice. Although patients in the IH 
program were encouraged to use services as frequently as possible, they were free to choose the 
relative frequency and duration of use, reflecting naturally occurring patterns of IH usage. No 
incentives were provided for participation due to lack of funding and use of services (type, 
frequency, and duration) was determined by the patient and was tracked by the research team. 
Additionally, all services were provided at set costs, paid by the patient.  
Integrative Healthcare Program  
The Integrative Healthcare (IH) program under study exists within an academic medical 
center and cancer institute and was designed to provide supportive and integrative therapies for 
cancer patients and their caregivers during all stages of cancer care. This IH program includes 
access to a variety of services that include: psychotherapy, massage therapy, acupuncture, yoga, 
reiki, and mind-body skills training. A variety of practitioners administer the services, from 
medically certified massage therapists and acupuncturists to graduate student therapists (under 
the supervision of a licensed clinical psychologist). It is important to note that mind-body 
services (i.e., meditation, relaxation, guided imagery, etc.) are generally included in integrative 
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healthcare programs (NCCIH, 2016), whereas the inclusion of traditional psychotherapy services 
marks a unique and distinguishing feature of this particular IH program.  
The duration, format (individual or group), and cost of services were varied. 
Psychotherapy was offered individually in 60-minute sessions, whereas massage therapy was 
offered at various time intervals ranging from 20- to 60-minute sessions. Acupuncture and yoga 
were offered in both individual and group sessions at varying time intervals (i.e., 30-, 45-, and/or 
60-minute sessions). Reiki was available individually (30- or 60-minute sessions), with the 
option to be received in conjunction with massage or yoga for a reduced price and duration (10-
minutes). The mind-body skills course is a 8-week course (8-sessions) that covers strategies for 
reducing stress, exploring emotions, and increasing mindfulness; this course was offered free-of-
charge for cancer patients, whereas all other services were paid services. These services were 
designed to be affordable, accessible, and competitive with community-based CAM services.   
Participants  
Participants were 178 adult cancer patients (84% female; 16% male), with a mean age of 
58.2 years (SD = 13.3) and a range of 18 to 87 years, recruited from a University Medical Center 
Cancer Institute. The majority (91%) of the sample was Caucasian, with a mean education level 
of 15.3 years (SD = 2.9). The most common cancer diagnosis among participants was breast 
cancer (43%), followed by lung cancer (7%) and multiple instances of cancer (6%). Given the 
breadth of cancer types included in the present study, cancer types were dichotomized into 
‘Breast’ (43%) and  ‘Other’ (57%) for the purpose of analyses (see Results section for additional 
information). Half of participants (50%) had lower stage cancers (0-2), and had received 
chemotherapy (56%) and/or radiation (42%) treatment. The average time since diagnosis was 
3.60 years (SD = 5.9).  
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Forty percent of the participants (n = 71) opted to engage in IH services between baseline 
and 12-month follow-up, attending IH services an average of 4.31 times (SD = 4.88; median = 3, 
mode = 1, range: 1 – 29). The most commonly used IH services included massage therapy 
(17%), followed by psychotherapy (12%) and acupuncture (10%). A subset of the sample (n = 
52; 29%) was randomized to a blood draw condition. Of those in the blood draw group, 
approximately 44% used IH services. A total of 169 participants were eligible for 3-month 
follow-up at the time of data analysis, and 124 (73%) completed the follow-up data collection 
(attrition rate = 27%). For 12-month follow-up, 117 participants were eligible for completion at 
the time of follow-up, with 79 (68%) completing the follow-up data collection (attrition rate = 
33%). Baseline characteristics and descriptive statistics of the participants at T2 are displayed in 
Table 1. 
Eligibility criteria for the present study were broad, in that patients ≥ 18 years of age 
were eligible for inclusion irrespective of cancer type, stage, and treatment status, as well as 
mental healthcare status (i.e., psychotherapy and/or psychiatry services) and participation in IH 
services in the community. Patients were excluded from participation if their initiation of IH 
services at the Cancer Institute occurred prior to the recruitment contact. With regard to IH 
usage, participants were classified into the IH usage group if they used one or more IH services 
(any type of service) at the medical center following baseline survey completion. Participants 
self-selected by opting into (or out of) IH usage, and usage of IH services (type, frequency, and 
duration) was tallied and tracked on an ongoing basis for each participant in the IH usage group.  
Procedure 
 The Institutional Review Board (IRB) at the University and University Medical Center 
approved the current study, and all participants were required to complete written informed 
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consent documents. Participants were recruited in-person at the Cancer Institute, as well as over 
the telephone. Those recruited in-person were approached in either the outpatient clinic waiting 
area or within the IH office at the Cancer Institute. Prospective participants for recruitment by 
telephone were identified via queries through the Tumor Registry Board or through IH records 
(i.e., newly scheduled participants were identified and contacted either before or at point-of-
service). All prospective participants identified through queries were sent an informational 
packet via postal mail and were informed that study staff would be in contact within two weeks 
of the mailing to assess interest.  
Study participants were asked to complete survey measures at three assessment intervals: 
baseline (T1; prior to use of IH services), 3-month follow-up (T2), and 12-month follow-up (T3). 
Participants completed questionnaires in-person, over the telephone, or online. A subset of the 
sample (approximately 30%) was randomized to a blood draw condition to assess immune 
system functioning via cytokine plasma levels. Participants were randomly allocated to the blood 
draw condition using a random number generator and were asked to consent to blood draws at 
the time of enrollment. Participants were requested to complete the study questionnaires on the 
same day as the blood draw, when applicable, at each respective time point (i.e., baseline, 3-
month, and 12-month follow-up). Blood samples were collected by registered nurses and trained 
phlebotomists working in the outpatient unit at the Cancer Institute, and all specimens were be 
sent to a hospital laboratory for analyses. All participants were assigned a Study ID number at 
study entry used to code survey and biological data.  
Measures in the present study assessed basic demographic information and cancer 
variables, including cancer type and stage, cancer treatment (type, duration, frequency), 
medications, and previous psychiatric care or psychotherapy. Measures also assessed primary 
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outcome variables, including depression, anxiety, somatic/physical symptoms, and health-related 
quality of life. Questions regarding use of community-based IH services were included for a 
subset of participants. All measures are available in the Appendix. 
Measures.  Demographics.  Participants completed a demographics questionnaire that 
assessed basic biographical data including age, gender, race, and socioeconomic status, as well 
as cancer-related variables, including type, stage, type of treatment and duration. Cancer 
information was also verified via medical records, when possible, with permission to obtain this 
information requested in the study consent form.  
Emotional Health and Physical Symptoms. The Patient Health Questionnaire (PHQ; 
Kroenke, Spitzer, & Williams, 2001; Spitzer, Kroenke, & Williams, 1999) was used to assess 
depression, anxiety, and somatic/physical symptoms at each time point. The PHQ is one of the 
most commonly administered self-report measures in medical settings (Wittkampf, Naeije, 
Schene, Huyser, & van Weert, 2007). While there are many different versions of the PHQ, the 
present study used the PHQ-9 (depression), GAD-7 (anxiety), and PHQ-15 (somatic and physical 
symptoms), totaling 31 multiple-choice items (see Appendix for measures).  These measures 
have been subject to meta-analytic review, with some evidence to suggest that this triad (i.e., 
PHQ-9, GAD-7, and PHQ-15) may be an efficient means for detecting and monitoring 
depressive, anxiety and somatic symptoms in primary care and other medical settings (Kroenke, 
Spitzer, Williams, & Lowe, 2010).  
The PHQ-9 is a 9-item self-report depression screener, asking patients how often in the 
past two weeks they have been bothered by depressive symptoms, such as “little interest or 
pleasure in doing things,” with responses ranging from 0 (“Not at all”) to 3 (“Nearly every day”; 
Kroenke et al., 2001). Similarly, the GAD-7 is a 7-item self-report anxiety scale that asks 
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respondents to rate how often they have been bothered by anxious symptoms, such as “not being 
able to stop or control worrying,” within the last two weeks, with responses ranging from 0 
(“Not at all”) to 3 (“Nearly every day”; Spitzer, Kroenke, Williams, & Lowe, 2006). The PHQ-
15 is a 15-item somatic symptom scale that asks respondents to indicate how often they have 
been bothered by somatic symptoms within the past 4 weeks, with responses ranging from 0 
(“Not bothered at all”) to 2 (“Bothered a lot”) and symptoms including stomach pain, back pain, 
headaches, and fainting spells, among others (Kroenke, Spitzer, & Williams, 2002). Cut-off 
points are similar across all measures, with scores of 5, 10, ≥15 representing mild, moderate, and 
severe levels of symptom burden (Kroenke et al., 2010). The most commonly recommended cut-
off score for sufficient sensitivity and specificity in detecting “clinically significant” symptoms is 
≥10 across scales (Kroenke et al., 2010). 
The reliability and validity of the PHQ scales is well established (Wittkampf et al., 2007), 
with the internal reliability of all scales, the PHQ-9 (α = .89; Kroenke et al., 2001), GAD-7 (α = 
.92; Spitzer et al., 2006), and PHQ-15 (α = .80; Kroenke et al., 2002), resting within the excellent 
range.  The internal consistency of the PHQ scales was comparable in the present study, as 
follows: PHQ-9 (α = .89), GAD-7 (α = .94), and PHQ-15 (α = .84). The test-retest reliability of 
the PHQ-9 and GAD-7 is also good to excellent (Kroenke et al., 2001; Spitzer et al., 2006), 
whereas the test-retest reliability of the PHQ-15 has been less extensively studied and appears to 
fall within the moderate range (Ravesteijn et al., 2009). Sensitivity to change, a characteristic of 
measures used to monitor treatment response, has been consistently established for the PHQ-9, 




Health-related Quality of Life (HRQOL).  The Center for Disease Control and 
Prevention’s Health-related Quality of Life measure (CDC-HRQOL-4; also referred to as the 
Healthy Days measure) was used to assess participants’ perceived physical and mental health 
status. Health-related Quality of Life (HRQOL) is a multi-dimensional concept that includes 
domains related to physical, mental, emotional and social functioning and goes beyond direct 
measures of population health by focusing on the impact health status has on quality of life 
(Moriarty, Zack, & Kobau, 2003). In fact, the CDC- HRQOL-4 measure has been shown to be 
predictive of morbidity and mortality and healthcare usage, and is often associated with chronic 
health conditions, health-risk behaviors, and other sociodemographic factors, such as gender and 
age (Zahran et al., 2005).   
The CDC-HRQOL-4 includes questions regarding perceived overall health and estimates 
of days (in the past 30 days) when physical health, mental health, and other activities (i.e., work, 
self-care, recreation) were impaired (Moriarty et al., 2003; Zahran et al., 2005). Some example 
questions include:  “Would you say your health is:  Excellent, Very Good, Good, Fair, or Poor?” 
and “Now thinking about your physical health, which includes physical illness and injury, for 
how many days during the past 30 days was your physical health not good?” Two additional 
modules were incorporated for the purpose of this study: the Activity Limitations Module and 
the Healthy Days Symptom Module, comprising the full set of Healthy Days measures or the 
CDC-HRQOL-14. The Activity Limitations Module assesses physical, mental, or emotional 
limitations on daily life and the extent and duration of impairment or health problem. The 
Healthy Days Symptom Module includes questions regarding days of pain, depressed mood, 
anxiety, sleeplessness, and vitality (i.e., healthy and full of energy). For the purpose of assessing 
HRQOL as an outcome variable, the following item was used and reverse-coded for ease of 
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interpretation: “Would you say that in general your health is:  Excellent, Very Good, Good, Fair, 
or Poor?” (reverse coded:  1 = poor to 5 = excellent).   
The CDC-HRQOL-4 and associated modules (i.e., full set of Healthy Days measures) 
have been used in the CDC’s Behavioral Risk Surveillance System (BRFSS) for over two 
decades, a nationwide survey with an emphasis on population health and disease prevention, and 
have demonstrated good reliability and validity with adults in this context (Moriarty et al., 2003; 
Zahran et al., 2005). The CDC-HRQOL-4 and full set of Healthy Days measures validly 
distinguish between disease groups and are regarded as valid and useful measures of health-
related quality of life with diverse populations of adults (Moriarty et al., 2003).  
Integrative Healthcare Usage. In addition to tracking usage of IH services from patient 
charts (type, frequency, and duration), a subset of participants were asked to self-report IH usage, 
including use of services both at the medical center and in the community. These participants 
were also asked to state reasons for using or not using IH services at the medical center for the 
purpose of determining potential barriers and improving future studies on IH usage. Self-
reported usage was captured for a subset of the sample only, as these items were added partway 
through the study as a means to capture patterns of use external to our IH program.  
Immune functioning. All biospecimens were processed in the university medical 
center’s laboratory following collection in the outpatient clinic at the Cancer Institute. Blood 
specimens were collected in red top/tiger top serum tubes with a gel-barrier for quantification of 
CRP. CRP levels were assessed by a latex immunoturbidimetric assay with a standard kit. For 
IL-6 processing, plasma was separated from cells and processed in a lavender-top (EDTA) tube. 
IL-6 levels were assessed by enzyme-linked immunoassay (ELISA) with a standard kit. Samples 
were processed according to standard blood specimen preparation procedures, including 
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refrigeration at 2-8°C and freezing at -15°C or colder (up to -30°C). Samples were centrifuged at 
3500 RPM at room temperature (20-25°C) for 10 minutes. 
Data Analytic Plan  
Descriptive statistics and correlations among primary study variables were computed 
using SPSS 22. Attrition analyses were run using cross-tabulation analyses in SPSS 22, with a 
Pearson Chi-Square test of significance. Binary logistic regression analyses were conducted in 
SPSS 22 to examine systemic differences between the IH usage and TAU groups at baseline 
(Aim 1; Sperandei, 2014). A dichotomous IH usage variable (0 = no usage; 1 = 1+ times used) 
was regressed onto a set of sociodemographic, emotional health, and cancer variables to explore 
factors associated with engagement in IH services. All sociodemographic and cancer variables 
were converted to dichotomous variables for the purpose of logistic regression analyses. 
Bivariate correlations were conducted with dichotomous and/or continuous variables, as per 
logistic regression analyses. 
To determine if IH usage is linked to outcome (criterion) variables (depression, anxiety, 
physical/somatic symptoms, quality of life, and immune function) at 3-month and 12-month 
follow-up (Aim 2), a series of regression analyses were examined for each outcome variable in 
SPSS 22, while controlling for baseline scores on the respective outcome measure (Mason & 
Perreault, 1991). The predictor variable (IH usage) was examined as both a dichotomous variable 
(0 = no usage; 1 = 1+ times used) and a count variable (i.e., dosage in minutes).  For a subset of 
the sample for which community usage data (dichotomous; yes = 1, no = 0) was collected, 
regression analyses were run to control for community usage, in addition to baseline levels of 
outcome variables. Missing data was handled via list-wise deletion, in which a participant’s data 
is excluded from analysis if one or more values are missing. Change in each outcome variable 
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was determined from two time points: baseline and 3-months, or baseline and 12-months, in an 
effort to explore short-term and long-term outcomes, respectively. A statistically significant 
parameter (p < .05) indicates that IH usage was predictive of a change in the outcome score, 
above and beyond the score at baseline, as represented by the following regression equation:  
Y (depression) = β(baseline dep)X(IH usage) + c(constant)  
Effect sizes were estimated for outcomes data, using Adjusted R2 values, which represent 
the proportion of variance in the outcome variable attributable to model predictors. Lastly, a 
series of t-tests and/or ANOVAs were run in SPSS 22 to further explore effect sizes by group 
(i.e., IH usage, community usage) and service type (i.e., acupuncture, massage, psychotherapy, 
etc.) for 3-month outcome analyses. Effect sizes were estimated for exploratory t-tests and 
ANOVAs using eta-squared values. Eta-squared values represent the proportion of variance in 
the outcome variable attributable to the predictor variable (Norouzian & Plonsky, 2018; 
















Correlations among predictor and outcome variables for logistic and multiple regression 
models are presented in Tables 2 and 3, respectively. In terms of demographics, gender and 
ethnicity were not significantly correlated with emotional health variables at T1 (baseline), T2 
(3-month follow-up), or T3 (12-month follow-up). Age and income level were associated with 
T1 (baseline) measures, such that cancer patients of younger age and lower income presented 
with elevated levels of depression, anxiety (age only), somatic symptoms (income only), and 
lower HRQOL. Income remained associated with these outcome measures at T2 (3-month) and 
T3 (12-month), and was uniquely associated with anxiety at T3 (12-month) only. Fewer years of 
education was associated with lower HRQOL at T1 (baseline) and T2 (3-month), and was 
marginally association with HRQOL at T3 (12-month). Marital status was not significantly 
correlated with baseline (T1) outcome variables; however, being unmarried was associated with 
elevated anxiety and somatic symptoms at T3 (12-month) only.  
Cancer-related variables were significantly associated with outcome variables across time 
points. Cancer type was positively correlated with T1 (baseline) measures, such that breast 
cancer was associated with fewer somatic symptoms and higher HRQOL at baseline. Cancer 
stage was significantly associated with T3 (12-month) outcome measures, such that advanced 
stage cancer was associated with higher levels of T3 depression, anxiety, somatic symptoms, and 
reduced HRQOL. Cancer stage also showed a positive correlation with T3 (12-month) 
biomarkers, specifically, IL-6. Cancer treatment (i.e., chemotherapy, radiation, and/or surgery) 
and years since diagnosis were not correlated with emotional health variables at baseline (T1) or 
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follow-up (T2 or T3).  However, chemotherapy displayed an association with elevations in T3 
(12-month) biomarkers, specifically, IL-6.  
In terms of IH usage, community usage and composite usage (IH + community usage) 
were not significantly associated with baseline or outcome variables. However, IH usage 
(dichotomous; 1 = yes, 0 = no) was correlated with T1 (baseline) depression, such that use of 
services was associated with increased depression at baseline (prior to use). 
Attrition analyses were conducted to assess factors associated with missingness at T2 (3-
month; attrition rate = 27%) and T3 (12-month; attrition rate = 33%).  Analyses revealed that 
socio-demographic variables (i.e., gender, age, ethnicity, marital status, income, and years of 
education) were not significantly associated with attrition at T2 (3-month) or T3 (12-month). 
With regard to cancer variables, cancer type (dichotomously coded: “Breast” or “Other”) was 
significantly associated with attrition at T2 (3-month), X2(1, n = 169) = 10.42, p =.001, and T3 
(12-month), X2(1, n = 117) = 17.42, p <.001, such that those with breast cancer were less likely 
to dropout at follow-up, as compared to those with other forms of cancer. Cancer stage was not 
significantly associated with attrition at T2 (3-month) or T3 (12-month).  Similarly, baseline (T1) 
depression, anxiety, somatic symptoms, and HRQOL were not predictive of T2 (3-month) or T3 
(12-month) attrition. Likewise, scores on emotional health measures at T2 (3-month) were not 
predictive of attrition at T3 (12-month). 
Primary Analyses 
 Aim 1. Factors associated with IH usage. Results from the logistic regression model are 
presented in Table 4. Consistent with study hypotheses, baseline depression (OR = 1.10, p ≤ .01) 
emerged as a significant predictor of engagement in IH services; for every one-unit increase in 
depression, there was a 9.5% increase in the odds of using IH services. Baseline anxiety (OR = 
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1.089, p ≤ .01) was also significantly predictive of engagement in IH services; for every one-unit 
increase in anxiety, there was an 8.9% increase in the odds of using IH services. Somatic 
symptoms (OR = 1.01, p = .83) and HRQOL (OR = 1.02, p = .92) at baseline (T1) were not 
predictive of IH engagement. Contrary to expectations, demographics variables (i.e., gender, age, 
ethnicity, marital status, income, and years of education) were not significant predictors of 
engagement in IH services. Similarly, cancer-specific variables (i.e., cancer type, cancer 
treatment, and years since diagnosis) did not emerge as significant predictors of engagement in 
IH services. Although radiation treatment emerged as a marginal predictor of IH usage in the 
depression model (OR = 0.45, p = .07), it did not emerge as a predictive factor in the anxiety 
model (OR = 1.41, p = .45), somatic symptoms model (OR = 0.56, p = .15), or the HRQOL 
model (OR = 0.53, p = .12).  
 Aim 2a. Outcomes at 3-month follow-up (T2). Results from regression models 
examining outcomes associated with (a) IH usage (dichotomous; 1 = yes, 0 = no) and (b) IH 
dosage (in minutes) at T2 (3-month follow-up), while controlling for baseline values of each 
respective outcome variable, are presented in Table 5.  Contrary to expectations, IH usage 
(dichotomous) and IH dosage (in minutes) did not emerge as significant predictors of depression 
at T2 (3-month).  Similarly, IH usage and IH dosage were not predictive of anxiety or somatic 
symptoms at T2. With regards to HRQOL, IH usage (β = 0.14, p ≤ .05) was found to be a 
predictor of greater HRQOL at T2, consistent with study hypotheses.  However, this finding did 
not remain for IH dosage (in minutes), which, inconsistent with study hypotheses, was not 
predictive of T2 HRQOL. When controlling for baseline levels of outcome variables (i.e., 
depression, anxiety, somatic symptoms, HRQOL), baseline scores were found to be predictive of 
T2 scores across outcomes measures. (See Table 5 for full results.) As a set, model predictors 
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explained approximately 38%, 37%, 49%, and 47% of the variance in T2 depression, anxiety, 
somatic symptoms, and HRQOL, respectively.  
 For immune outcomes, IH usage (dichotomous) and IH dosage (in minutes) were not 
predictive of T2 (3-month) levels of C-Reactive Protein (CRP), contrary to study hypotheses. 
Also, contrary to expectations, IH usage and IH dosage were not predictive of T2 (3-month) 
levels of Interleukin-6 (IL-6). When controlling for baseline (T1) levels of immune biomarkers, 
baseline CRP and baseline IL-6 were predictive of T2 levels of CRP and IL-6. (See Table 5 for 
full results.) As a set, these model predictors accounted for roughly 35% and 56% of the variance 
in CRP and IL-6, respectively.  
Outcome analyses with a subset (n = 76) with community usage data. Results from 
regression models with a subset of the sample (n = 76) from which community usage data was 
collected is presented in Table 6; regression models examined outcomes associated with (a) IH 
usage (dichotomous; 1 = yes, 0 = no) and (b) IH dosage (in minutes), while controlling for 
community usage (dichotomous; 1 = yes, 0 = no) and baseline values of each respective outcome 
variable (i.e., depression, anxiety, etc.). Similar to earlier findings and contrary to study 
hypotheses, IH usage (dichotomous) and IH dosage (in minutes) did not emerge as significant 
predictors of depression at T2 (3-month follow-up) in the subset. Similarly, IH usage and IH 
dosage were not predictive of T2 anxiety, nor were usage and dosage predictive of T2 somatic 
symptoms (See Table 6 for full results). However, consistent with hypotheses, IH usage emerged 
as a predictor of greater HRQOL at T2 (β = 0.20, p ≤ .05), such that IH usage was predictive of 
increased HRQOL at 3-month follow-up (T2). This finding did not remain when examined for 
IH dosage (i.e., usage in minutes), which, inconsistent with study hypotheses, was not predictive 
of T2 HRQOL. When controlling for community usage (dichotomous; 1 = yes, 0 = no) in the 
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subset, self-reported community usage was not predictive of T2 depression, T2 anxiety, T2 
somatic symptoms, or T2 HRQOL in either model. When controlling for baseline levels of 
outcome variables, baseline (T1) scores of depression, anxiety, somatic symptoms, and HRQOL 
were predictive of respective T2 scores across all outcomes measures. As a set, model predictors 
explained roughly 32%, 32%, 53%, and 38% of the variance in T2 (3-month) depression, 
anxiety, somatic symptoms, and HRQOL, respectively.  
For immune outcomes, contrary to hypotheses, IH usage and IH dosage were not 
predictive of T2 levels of C-Reactive Protein (CRP) or T2 Interleukin-6 (IL-6). When controlling 
for community usage (dichotomous; 1 = yes, 0 = no) in the subset, community usage was not 
predictive of T2 levels of CRP or IL-6. When controlling for baseline levels of biomarkers, 
baseline CRP was not predictive of T2 levels of CRP; however, baseline levels of IL-6 were 
predictive of T2 levels of IL-6 in both models. (See Table 6 for full results.) As a set, these 
model predictors accounted for 38% and 63% of the variance in CRP and IL-6, respectively.  
Outcome analyses for IH and community usage examined as a composite variable. 
Results from regression models examining outcomes associated with composite usage 
(dichotomous; 1 = yes to either, 0 = participation in neither), while controlling for baseline 
values of each respective outcome variable (i.e., depression, anxiety, etc.) are presented in Table 
7.  Similar to prior findings and contrary to study hypotheses, composite usage (IH usage + 
community usage; dichotomous) did not emerge as a significant predictor of T2 (3-month) 
depression, T2 anxiety, or T2 somatic symptoms. Also contrary to study hypotheses, and 
inconsistent with prior findings, composite (combined) usage was not predictive of T2 HRQOL. 
When controlling for baseline levels of outcome variables (i.e., T1 depression, anxiety, somatic 
symptoms, HRQOL), baseline (T1) scores were found to be predictive of respective T2 (3-
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month) scores across all outcomes measures. (See Table 7 for full results.) As a set, model 
predictors accounted for 32%, 31%, 53%, and 40% of the variance in T2 (3-month) depression, 
anxiety, somatic symptoms, and HRQOL, respectively. 
For immune outcomes, consistent with hypotheses, composite (combined) usage emerged 
as a predictor of T2 (3-month) levels of C-Reactive Protein (CRP; β = -0.59, p ≤ .05) and 
Interleukin-6 (IL-6; β = -0.34, p ≤ .05), such that increased usage (IH + community usage) was 
associated with lower levels of circulating CRP and IL-6. When controlling for baseline levels of 
biomarkers, baseline CRP was not predictive of T2 levels of CRP; however, baseline levels of 
IL-6 were predictive of T2 (3-month) levels of IL-6. (See Table 7 for full results.) As a set, these 
model predictors accounted for 65% and 74% of the variance in CRP and IL-6, respectively.   
Exploratory analyses.  Exploratory analyses by type of IH service revealed a significant 
effect on mean change scores for depression from T1 (baseline) to T2 (3-month) by type of IH 
service (i.e., massage, psychotherapy, and acupuncture), F(3, 45) = 4.93, p ≤ .01. Results 
indicated that participants who engaged in psychotherapy experienced a greater reduction in 
symptoms of depression from T1 to T2 (M = -7.71, SD = 7.54), relative to participants engaged 
in massage therapy (M = -1.65, SD = 3.27) or acupuncture (M = -1.50, SD = 2.46) services, with 
26.5% of the variance in mean change scores of depression accounted for by IH service type. 
Similarly, a significant effect on mean change scores for anxiety (T2-T1) by type of IH service 
was detected, F(3, 43) = 5.86, p ≤ .01, such that participants engaged in psychotherapy 
experienced a greater reduction in symptoms of anxiety from T1 to T2 (M = -6.07, SD = 5.74), 
relative to participants engaged in massage therapy (M = -0.78, SD = 3.95) or acupuncture (M = 
0.60, SD = 2.67) services. Results revealed that type of service accounted for approximately 
31.1% of the variance in mean change scores (T2-T1) for anxiety. No main effect was detected 
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for type of IH service with respect to mean change scores (T2-T1) for somatic symptoms, F(3, 
45) = 1.67, p = .188, or HRQOL, F(3, 45) = 0.175, p = .913. There were no difference in mean 
change scores for somatic symptoms based on participation in massage therapy, psychotherapy, 
or acupuncture services, nor was there as difference in mean change scores for HRQOL based on 
participation in massage therapy, psychotherapy, or acupuncture.  Of the variance in mean 
change scores for somatic symptoms and HRQOL, type of service accounted for approximately 
10.9% and 1.3%, respectively. (See Table 8 for full results.) 
Exploratory analyses of IH usage (dichotomous; 1 = yes, 0 = no) revealed a significant 
effect on mean change scores for depression from T1 (baseline) to T2 (3-month) by status of IH 
usage, t(120) = 2.70, p ≤ .01, such that participants who self-selected into IH services 
experienced greater reductions in depression (M = -3.58, SD = 5.55) relative to participants who 
opted into TAU (M = -0.97, SD = 4.90). IH usage accounted for approximately 5.7% of the 
variance in mean change scores in depression from T1 to T2. A significant difference in mean 
change scores (T2-T1) was also detected for HRQOL based on status of IH usage, t(120) = -2.39, 
p ≤ .05, such that participants who self-selected into IH services were more likely to experience 
improvements in HRQOL (M = 0.16, SD = 0.95) as compared to participants who opted into 
TAU (M = -0.23, SD = 0.79). Participation in IH usage explained approximately 4.6% of the 
variance in mean change scores for HRQOL. No main effect was detected for IH usage with 
respect to mean change scores (T2-T1) for anxiety, t(116) = 1.29, p = .20, or somatic symptoms, 
t(117) = 0.47, p = .638. There was no difference in mean change scores for anxiety or somatic 
symptoms based on self-selection into IH usage versus TAU. (See Table 9 for full results.) Of 
the variance in mean change scores for anxiety and somatic symptoms, IH usage accounted for 
approximately 1.4% and 0.2%, respectively.  
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Exploratory analyses of community usage (dichotomous; 1 = yes, 0 = no) for a subset of 
the sample for which this data was available revealed a significant main effect with respect to 
mean change scores (T2-T1) for anxiety, t(72) = -2.37, p = .02, such that participants who self-
reported community usage were less likely to experience reductions in anxiety (M = 0.58, SD = 
4.24) from T1 to T2, relative to participants who did not report use of services in the community 
(M = -1.94, SD = 4.32). Community usage explained approximately 7.2% of the variance in 
mean change scores in anxiety from T1 to T2. No significant effect was found for community 
usage with respect to mean change scores  (T2-T1) for depression, t(75) = -1.30, p = .20, somatic 
symptoms, t(73) = -1.73, p = .09, or HRQOL, t(74) = 0.33, p = .75. Based on community usage, 
there was no difference in mean change scores (T2-T1) for depression, somatic symptoms, or 
HRQOL. (See Table 10 for full results.) Of the variance in mean change scores for depression, 
somatic symptoms, and HRQOL, community usage accounted for approximately 2.2%, 3.9%, 
and 0.1%, respectively. 
Aim 2b. Outcomes at 12-month follow-up (T3).  Results from regression models 
examining outcomes associated with (a) IH usage (dichotomous; 1 = yes, 0 = no) and (b) IH 
dosage (in minutes) at T3 (12-month follow-up), while controlling for baseline values of each 
respective outcome variable, are presented in Table 11.  Contrary to expectations, IH usage 
(dichotomous) and IH dosage (in minutes) did not emerge as predictors of T3 (12-month) 
depression, T3 anxiety, T3 somatic symptoms, or T3 HRQOL.  When controlling for baseline 
levels of outcome variables, baseline (T1) levels of outcomes (i.e., T1 depression, T1 anxiety, T1 
somatic symptoms, and T1 HRQOL) were positive predictors of T3 outcomes. (See Table 11 for 
full results.)  As a set, model predictors explained 51%, 36%, 47%, and 42% of the variance in 
T3 (12-month) depression, anxiety, somatic symptoms, and HRQOL, respectively.  
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For immune outcomes, contrary to study expectations, IH usage (dichotomous) and IH 
dosage (in minutes) were not predictive of T3 (12-month) levels of C-Reactive Protein (CRP). 
Similarly, IH usage (dichotomous) was not predictive of T3 (12-month) levels of Interleukin-6 
(IL-6); however, IH dosage (in minutes) was a significant predictor of T3 (12-month) IL-6 (β = -
0.58, p ≤ .01), such that increased dosage in minutes was predictive of lower levels of circulating 
IL-6 in a subset of the sample.  When controlling for baseline levels of biomarkers, baseline 
levels of IL-6 were significantly predictive of T3 (12-month) levels of IL-6, whereas baseline 
CRP was not consistently predictive of T3 (12-month) CRP across models. (See Table 11 for full 
results.) As a set, these model predictors accounted for roughly 17% and 54% of the variance in 
CRP and IL-6, respectively.   
Outcome analyses with a subset (n = 36) with community usage data. Results from 
regression models with a subset of the sample (n = 36) from which community usage data was 
collected is presented in Table 12; regression models examined outcomes associated with (a) IH 
usage (dichotomous; 1 = yes, 0 = no) and (b) IH dosage (in minutes) at T3 (12-month follow-up), 
while controlling for community usage (dichotomous; 1 = yes, 0 = no) and baseline values of 
each respective outcome variable (i.e., depression, anxiety, etc.).  Contrary to expectations, IH 
usage (dichotomous) and IH dosage (in minutes) were not predictive of T3 (12-month) 
depression, T3 anxiety, T3 somatic symptoms, and T3 HRQOL. When controlling for 
community usage (dichotomous; 1 = yes, 0 = no) in the subset, self-reported community usage 
was not predictive of T3 depression, T3 anxiety, T3 somatic symptoms, or T3 HRQOL.  When 
controlling for baseline levels of outcome variables, baseline (T1) levels of outcomes (i.e., T1 
depression, T1 anxiety, T1 somatic symptoms, and T1 HRQOL) were positive predictors of 
respective T3 (12-month) outcomes. (See Table 12 for full results.) As a set, model predictors 
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accounted for 48%, 20%, 48%, and 41% of the variance in T3 (12-month) depression, anxiety, 
somatic symptoms, and HRQOL, respectively, in this subset of the sample.  
Outcome analyses for IH and community usage examined as a composite variable. 
Results from regression models examining outcomes associated with composite usage 
(dichotomous; 1 = yes to either, 0 = participation in neither) at T3 (12-month follow-up), while 
controlling for baseline values of each respective outcome variable (i.e., depression, anxiety, 
etc.) are presented in Table 13.  Contrary to study hypotheses, composite (combined) usage did 
not emerge as a predictor of T3 (12-month) depression, T3 anxiety, T3 somatic symptoms, or T3 
HRQOL. When controlling for baseline levels of outcome variables, baseline (T1) levels of 
depression, anxiety, somatic symptoms, and HRQOL were found to be positively predictive of 
respective T3 (12-month) outcomes. (See Table 13 for full results.) As a set, model predictors 
accounted for 49%, 17%, 45%, and 43% of the variance in T3 (12-month) depression, anxiety, 















 Integrative and holistic care is of growing interest among the general public as well as 
cancer patients, with rates of usage increasing and the demand for services generating a need for 
research examining the effectiveness of these interventions (Barnett & Shale, 2012).  Research 
on the efficacy of integrative medicine for improving emotional and physical health outcomes is 
on the rise; however, much research remains to be conducted in this area. Complementary health 
approaches, such as yoga, acupuncture, massage therapy, and mind-body approaches, have been 
demonstrated as efficacious in the short-term with both cancer and non-cancer patients; however, 
the long-term effectiveness of these interventions remains largely unknown due to a dearth of 
longitudinal studies (Baker et al., 2012; Barnett & Shale, 2012). Methodological issues 
notwithstanding, the short-term benefits of integrative programs have been noted to broadly 
include improvements in depression, anxiety, quality of life, immune function, and 
physical/somatic symptoms, including those symptoms that occur as a result of cancer treatment, 
such as pain or neuropathy, fatigue, and hot flashes (e.g., Baker et al., 2012; Barnett & Shale, 
2012; Deng & Cassileth, 2005a; Lin et al., 2011; Subnis et al., 2014). The present study explored 
the short-term (3-month) and long-term (12-month) emotional, physical/somatic, and immune 
benefits of an integrative healthcare (IH) program for cancer patients, as well as factors 
influencing engagement in IH services in a cancer care setting.   
In terms of factors influencing IH usage, depression and anxiety emerged as significant 
predictors of engagement in our IH program; cancer patients who elected to participate in our 
program were more likely to be anxious and depressed, as compared to those who opted for 
treatment as usual (TAU). All other emotional or physical health variables (i.e., HRQOL, 
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physical/somatic symptoms) were not significantly associated with engagement in our IH 
program, nor were socio-demographic or cancer-related variables (e.g., cancer type, cancer 
treatment). Notably, our findings indicate that depressed and anxious cancer patients may be 
more likely to seek complementary health approaches to augment standard cancer care, 
presenting healthcare providers (e.g., oncologists, social workers, psychologists, etc.) with an 
opportunity to identify, educate, and assist such patients in determining which services would be 
most likely to complement their care and provide symptom relief (Barnett & Shale, 2012).  
Although previous research has been mixed with regard to the predictive power of 
emotional distress (e.g., Astin, 1998; Fouladbakhsh & Stommel, 2010), our study contributes to 
the evidence to suggest that depression and anxiety may be amongst the factors driving cancer 
patients to seek integrative and holistic care. In fact, our findings suggest that depression and 
anxiety may be predictive of IH usage, above and beyond other factors, such as patient- and 
treatment -related variables. This marks a deviation from previous research, which has found 
strong support for gender as a predictor of IH usage and lesser, or more mixed, support for other 
sociodemographic and cancer-related variables (Barnes et al., 2004; Fouladbakhsh & Stommel, 
2008, 2010). These results provide important information about who might be seeking integrative 
care in an oncology setting, pointing toward depression and anxiety as important contributing or 
motivating factors for engagement in integrative care; however, future research is needed to 
substantiate this finding and to further understand its implications for the delivery of integrative 
care in this setting.   
With regard to the effectiveness of the intervention, improvements in health-related 
quality of life (HRQOL) were evidenced for IH participants at T2 (3-month follow-up); however, 
these gains were not maintained at T3 (12-month follow-up). Contrary to expectations, IH 
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program participation was not predictive of reductions in depression, anxiety, or somatic 
symptoms at T2 (3-month) or T3 (12-month). However, exploratory analyses at T2 suggested 
that those who elected to participate in IH services experienced greater reductions in depression, 
in addition to improvements in HRQOL, when compared to those engaged in TAU. Although 
significant reductions in depression were not evidenced when examining outcomes from baseline 
to T2 (3-month follow-up), it is possible that IH usage may have an effect on depression that we 
were unable to detect, due to issues of power and/or attrition. As a whole, our findings indicate 
that IH usage may confer short-term benefits in HRQOL to cancer patients. Exploratory analyses 
at T2 provided substantiating evidence by suggesting that improvements in HRQOL were not 
related to any specific service type (e.g, psychotherapy, acupuncture, or massage therapy), but 
instead may be related more globally to participation in an IH program; or, alternatively, to some 
other factor not measured here.  While we did not find evidence for long-term effects on HRQOL 
or other emotional health outcomes, it is possible that our study was underpowered to detect an 
effect, given the smaller sample size at T3 (12-month follow-up).   
Of note, the short-term benefits in HRQOL appear to be specific to an IH program 
embedded within a cancer center, as opposed to IH usage defined more broadly (i.e., IH services 
provided in the community). That is, improvements in HRQOL were not evidenced when 
examined according to self-reported use of IH services received in the community, nor were 
these gains witnessed in those who participated in composite (combined) usage (i.e., community 
usage in conjunction with our IH program). Thus, our findings imply that short-term benefits in 
HRQOL for cancer patients may be specific to integrative care offered internally within an 
oncology setting, as opposed to externally (in the community).  It is important to note that 
community usage data was only available for a subset of the sample and may not be 
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representative of the range of complementary health services provided in community settings, 
limiting our ability to draw firm conclusions or comparisons from the data on community (or 
composite) usage. Additional research is needed to substantiate these findings and to allow for 
further exploration of the benefits of complementary and integrative health approaches offered 
within cancer care settings, as compared to those offered externally in the community.  
With regard to the clinical meaningfulness of the observed change in HRQOL at T2, it 
should be noted that the overall magnitude of this change was relatively small; thus, it is difficult 
to determine how this change in HRQOL would translate to observable changes in the lives of 
cancer patients. The mechanisms associated with changes in HRQOL with IH usage are also 
unclear at this time. While it is plausible that cancer patients may experience cognitive or 
behavioral shifts preceding and/or following participation in an integrative care program in a 
cancer care center, these pathways are not well delineated in the literature and are in need of 
further exploration. To increase the clinical meaningfulness of findings, future studies may 
benefit from using behavioral markers, in addition to self-report measures, to capture changes 
that occur over time. Such an addition would be especially helpful in ascertaining real-world 
behavioral changes that may be related to potential improvements in HRQOL and overall 
wellbeing with IH intervention. Whereas the present study suggests that cancer patients may 
experience global improvements in HRQOL in the short-term, it does not lend itself to a deeper 
understanding of the nature of these improvements, as experienced in the lives of cancer patients.  
Given our findings regarding who is seeking integrative care in a cancer care setting, the 
lack of impact of our intervention in the short- and long-term on depression and anxiety, as well 
as on somatic symptoms, indicates an important area of growth. That is, depressed and anxious 
cancer patients appear to be more inclined to seek integrative care, but do not appear to be 
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experiencing a significant reduction in depression and anxiety symptoms, nor do their symptoms 
appear to be worsening, in the course of their care. This finding is suggestive of an opportunity 
to more thoroughly assess and target depression and anxiety at the outset of participation in an 
IH program. One way to achieve this end would be to more extensively integrate psychological 
services with IH programs, which constitutes a vision for the future of holistic care that has 
recently emerged in the literature (Barnett & Shale, 2012). In fact, a unique feature of the current 
study is that our IH program offered traditional psychotherapy services alongside complementary 
health approaches. Whereas most programs offer mind-body and/or relaxation skills, our study is 
one of the first that we know of to examine traditional psychotherapy services offered as a part of 
an IH program for cancer patients. Exploratory analyses at T2 also offered support in favor of 
incorporating mental health care with integrative care to more effectively target depression and 
anxiety in cancer patients. That is, participants engaged in psychotherapy services in our study 
experienced greater improvements in depression and anxiety, as compared to those engaged in 
acupuncture or massage therapy, offering some evidence in support of the potential benefits of 
traditional mental health services for improving emotional health in an integrative oncology 
setting. Psychotherapy services may be a valuable component of integrative care in a cancer care 
setting and may complement integrative programs by effectively mitigating emotional distress 
(Barnett & Shale 2012). Given the prevalence and negative impact of depression and anxiety on 
cancer outcomes, including but not limited to mortality, effective psychosocial interventions are 
an especially pertinent area of development not only for integrative oncology, but also for cancer 
care more broadly (Knopf & Head, 2012; Spiegel & Giese-Davis, 2003).      
With regard to immune outcomes, limited evidence emerged to support improvements in 
immune health following engagement in our IH program. That is, IH usage was not predictive of 
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improvements in immune functioning at T2, although a unique effect was detected at T3. 
Specifically, IH dosage (in minutes) emerged as predictive of T3 (12-month) levels of IL-6, with 
increased minutes of exposure to IH services associated with lower levels of circulating IL-6. 
Although this finding is promising, it should be interpreted with caution due to the small sample 
size (n = 14) of the subset allocated to the blood draw condition at T3. Another interesting 
finding regarding immune functioning emerged at T2 (3-month) when combining IH usage 
(dichotomous) with self-reported community usage to form a composite variable (dichotomous). 
Although neither IH usage nor community usage were independently predictive of improvements 
in immune health, composite usage emerged as a predictor of lower levels of circulating IL-6 and 
CRP at T2, suggesting that combined usage (i.e., community usage in conjunction with our IH 
program) may confer unique physical health benefits to cancer patients. This finding is notable 
and warrants more systematic exploration, given limitations associated with a current sample 
(i.e., subset only) and inconsistent results regarding composite usage across models. Nonetheless, 
our study lends some support to the evidence in support of improved immune functioning for 
cancer patients engaged in integrative care (see Subnis et al., 2014), albeit limited and 
inconsistent in nature. Very few studies have examined CRP as an immune outcome for cancer 
patients, with IL-6 being more consistently linked to immune functioning in cancer populations 
comparatively (Musselman et al., 2001). Given the overall limited effect detected for immune 
outcomes in the current sample, it is difficult to determine whether CRP is as reliable of an 
outcome measure as IL-6, although some inconsistencies were observed (i.e., slightly lesser 
effect detected for CRP, by comparison).  
Overall, our study contributes to the body of evidence in support of the short-term 
benefits of integrative healthcare for cancer patients. Specifically, our findings lend support to 
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the notion of improved health-related quality of life (HRQOL) following participation in an IH 
program embedded within a cancer center.  Finally, our data provide some clues regarding who 
is seeking integrative care in a cancer setting and subsequent areas of improvement for 
integrative programs. While depressed and anxious cancer patients were more inclined to seek 
integrative services in our study, they did not appear to be experiencing significant symptom 
improvement in this area. These findings suggest that cancer patients engaged in IH may be more 
likely to experience global benefits to overall health, as opposed to improvements in depressive, 
anxious, or somatic symptoms. Thus, cancer patients may benefit from a more extensive 
incorporation of psychological and integrative healthcare services to improve depressive and 
anxious symptomology, as well as overall emotional health and wellbeing. Our study is the first 
that we know of to explore traditional psychotherapy services offered within an integrative 
program at a cancer care center. We hope our data motivate future research on the integration of 
psychological services and CAM, as growing public interest and demand for holistic care is 
likely to only increase the need for further integration of care (Barnett & Shale, 2012).  
Limitations and Future Directions  
Although this study has its inherent strengths, it is not without its limitations. The present 
study was intended as a pilot study and employed a longitudinal, open-trial (non-controlled) 
design, allowing participants to self-select into services of their choosing. While this design 
approximates usage in a natural (real-world) setting, it does not lend itself to systematic 
exploration of the benefits of IH usage. Thus, future research would benefit from employing an 
experimental design, such as a randomized controlled trial (RCT), more conducive to 
systematically exploring outcomes associated with IH usage and controlling for potential 
confounds. Further, given the nature of the study design, the findings do not allow for causal 
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inferences regarding the effect of IH usage on emotional and immune health outcomes, nor do 
the findings reveal specific mechanisms by which IH usage may improve outcomes, namely 
health-related quality of life (HRQOL).  However, the findings allow for tentative conclusions 
about the relationship between IH usage and improvements in HRQOL in cancer patients 
utilizing services offered within a cancer care setting; future longitudinal controlled trials would 
be better suited to explore causality and potential casual mechanisms within this context. An 
additional limitation stemming from our open-trial design pertains to the uncontrolled nature of 
frequency of IH use. In the current sample, frequency of use among those who self-selected into 
the IH usage group was relatively low, with 40% of the sample using services and frequency of 
use ranging from 1 to 29 times, with an average of 4.31 IH encounters.  The low rate of use in 
the current sample, in conjunction with the uncontrolled nature of the design, may have limited 
our ability to detect an effect. Future randomized controlled trials (RCTs) would allow for a 
greater degree of control over frequency of use and dosage effects in order to determine the 
unique contribution of integrative care to improvements in emotional and immune functioning.   
An additional limitation of the current study relates to attrition; it is important to note that 
those who did not complete follow-up data collection may differ from those who completed one 
or both of the follow-ups (e.g., mortality, severity of diagnosis, emotional distress, etc.). In 
particular, attrition is an especially salient issue for our blood-draw condition, which was limited 
to a subset of the sample (30%), rendering immune results more susceptible to the effects of 
attrition due to a smaller sample size. In addition, immune results may also be impacted by rates 
of use, with only 44% of the blood draw group using services, as well as by the broad range of 
cancer diagnoses and treatments captured in the current sample. Cancer treatment is known to 
exert an effect on immune functioning (e.g., see Miller et al., 2008); thus, examining effects of 
 
 47 
IH usage on immune functioning with a sample spanning the cancer care continuum may have 
introduced a wealth of potential confounds, or noise, rendering interpretation particularly 
problematic. Thus, immune results should be interpreted with extreme caution. Future studies 
would benefit from employing a controlled design (e.g., RCT) with a more robust sample, 
wherein cancer variables, such as type, stage and treatment, are more systematically controlled in 
order to more clearly distinguish effects on immune functioning. 
Furthermore, data on community usage of IH services was collected only for a subset of 
the sample (43% of the overall sample), as noted previously, and was limited to self-report data. 
As such, findings with regard to community usage may be limited in their generalizability, as the 
full range of community services and relative benefits may not be accurately represented by the 
subset. Future studies should examine community usage more systematically from the outset to 
capture the effects alone and/or in conjunction with integrative oncology programs. 
Understanding the prevalence of community use may also be of interest to healthcare providers 
(i.e., oncologists, nurses, psychologists, etc.), who have the responsibility of informing cancer 
patients of the unique benefits and potential contraindications of integrative services for overall 
emotional health and wellbeing (Deng & Cassileth, 2005a; Barnett & Shale, 2012). 
To some extent, our study may have been limited in its power to detect effects, due to 
issues of design (open-trial) and relatedly, dosage and attrition, as discussed above. It is 
important to note that our findings are suggestive of fewer overall benefits to emotional health, 
with benefits limited primarily to HRQOL, as compared to previous research on integrative 
programs indicating improvements in a broader range of outcomes, including depression, 
anxiety, and physical/somatic symptoms (e.g., see Baker et al., 2012; Deng & Cassileth, 2005a). 
Additionally, issues of power may also be pertinent to our long-term (12-month) analyses and 
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those using only a subset of the sample, namely our immune and community usage analyses. 
Although T3 (12-month) findings were mostly consistent with those at T2 (3-month), with some 
exceptions, we may have been limited in our ability to detect long-term effects due to sample 
size. Lastly, our study may have been limited in its ability to detect change in physical/somatic 
symptoms, due lesser-established test-retest reliability and sensitivity to change for the PHQ-15 
measure (Kroenke et al., 2010; Ravesteijn et al., 2009), which assesses a broad range of 
physical/somatic symptoms. Future studies may benefit from using a more sensitive or specific 
measure, targeting specific physical/somatic symptoms, such as cancer-related pain or fatigue, to 
elucidate potential change in these symptoms over time.  
Despite its limitations, the current study has several strengths, including its longitudinal 
design and inclusion of patients spanning the cancer care continuum. While this study was 
intended as a pilot study and employed a non-controlled design, it effectively captures natural 
patterns of usage that reflect what might be expected in a real-world integrated oncology setting. 
Taken as a whole, our findings suggest that integrative care, offered as an adjunct to standard 
cancer care, may confer short-term benefits to cancer patients, particularly with regard to health-
related QOL. Our study presently offers limited evidence in support of the long-term benefits of 
integrative care. Our findings also suggest that depressed and anxious cancer patients may be 
more inclined to seek integrative care but may not be maximally benefitting from IH 
intervention. Our findings provide some evidence to suggest that the incorporation of psychology 
services with integrative care may increase overall efficacy with regard to the alleviation of 
depressive and anxiety symptoms in cancer patients. Future researchers and clinicians should 
continue to investigate the ways in which integrative care may be further integrated with 
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Table A-1.   
Baseline characteristics and descriptive statistics of participants  
  By self-selection at T2 
 Full sample  
(n = 178) 
IH usage 
(n = 61) 
Control 
(n = 108) 
Gender, n (%)      
   Female 149 (84%) 52 (85%) 90 (83%) 
   Male 29 (16%) 9 (15%) 18 (17%) 
Age, M (SD) 58.2 (13.3) 56.9 (12.7) 58.1 (13.5) 
   Range 18 – 87    
Ethnicity, n (%)    
   Caucasian 162 (91%) 57 (95%) 96 (89%) 
   Other 15 (8%) 3 (5%) 12 (11%) 
Marital Status, n (%)     
   Married 97 (55%) 40 (67%) 50 (47%) 
   Not Married  79 (44%) 20 (33%) 57 (53%) 
Income, n (%)    
   Below 50K 95 (53%) 30 (51%) 63 (59%) 
   Above 50K 79 (44%) 29 (49%) 43 (41%) 
Years of Education, M (SD)  15.3 (2.9) 15.4 (2.8) 15.3 (3.0) 
   Range 10 - 26   
Cancer Type, n (%)     
   Breast 76 (43%) 26 (43%) 46 (43%) 
   Other 102 (57%) 35 (57%) 62 (57%) 
Cancer Stage, n (%)    
   Stage 0-1 58 (33%) 19 (28%) 36 (37%) 
   Stage 2 30 (17%) 10 (20%) 18 (19%) 
   Stage 3 42 (24%) 16 (31%) 23 (24%) 
   Stage 4 27 (15%) 6 (12%) 20 (21%) 
Chemotherapy, n (%) 100 (56%) 35 (60%) 59 (63%) 
Radiation, n (%) 74 (42%) 30 (52%) 37 (39%) 
Surgery, n (%) 68 (38%) 27 (47%) 37 (39%) 
Years since Dx, M (SD) 3.60 (5.9) 3.76 (5.9) 3.14 (5.1) 
   Range 0 – 30   
Baseline depress, M (SD) 8.00 (6.4) 9.75 (6.8) 7.11 (6.0) 
Baseline anx, M (SD) 6.18 (6.0) 7.52 (6.3) 5.45 (5.7) 
Baseline somatic, M (SD) 9.06 (5.3) 9.43 (4.5) 9.03 (5.8) 
































Note. *p < .05; **p < .01;  IH usage (1 = Yes; 0 = No) reflects overall use of services (i.e., usage at most recent time point).  
 
Table A-2.  
Correlations among Predictor Variables and IH usage 
Variables 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
1. Gender -                 
2. Age  -.07  -                
3. Ethnicity -.03 -.09 -               
4. Marital Status  -.25** .02  -.05 -              
5. Income -.12 .10 -.10 .37** -             
6. Years of Education -.09 -.03 .08 .01 .16* -            
7. Cancer Type -.38** -.01 .02 -.07 -.10 -.07 -           
8. Cancer Stage -.14 .09 -.10 .01 -.01 -.08 .39** -          
9. Chemotherapy -.06 -.10 -.07 -.18* .06 -.05 . 18* .44** -         
10. Radiation .03 .15 -.07 .06 -.13 -.07 -.11 .02 .03 -        
11. Surgery .20** -.03 .09 .06 .11 -.07 -.36** -.31** -.29** -.01 -       
12. Years Since Diagnosis -.02 .28** -.01 -.06 .02 -.08 -.01 .00 -.02 .11 .09 -      
13. Dep (PHQ-9) baseline -.04 -.18* -.07 -.10 -.25** -.07 .13 -.00 -.03 -.07 -.06 -.06 -     
14. Anx (GAD-7) baseline .02 -.20** -.06 -.11 -.11 -.05 .05 .01 .08 -.06 .01 -.00 .81**     
15. Som (PHQ-15) baseline .01 -.07 -.01 -.14 -.28** -.02 .16* .05 -.02 .04 -.00 -.07 .65** .50** -   
16. HRQOL baseline .12 .16* .07 .08 .15* .20* -.18* -.11 -.05 -.01 .07 .07 -.52** -.40** -.56** -  
17. IH usage (dichotomous)  .02 -.02 -.12 .17* .11 .06 .01 -.04 -.03 .10 .03 -.02 .18* .14 .01 -.01 - 
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Note: *p < .05; **p < .01; IH usage (1 = Yes; 0 = No) reflects overall use of services (i.e., usage at most recent time point);  
Community and composite usage (1 = Yes; 0 = No) apply only to a subset of the sample for which this data was available.
Table A-3.   
Correlations among demographics and IH variables with outcomes by time point  





































Demographics                   
Gender -.04 .02 .01 .12 -.23 -.24 .08 .06 .16 -.05 .20 .12 .001 -.03 .03 .04 .30 .20 
Age -.18*  -.20** -.07 .16* .05 .14 -.09 -.15 -.10 .01 .26 .28 -.19 -.16 -.19 .08 .08 -.15 
Ethnicity -.07 -.06 -.01 .07 -.08 -.11 -.05 -.03 -.02 .16 -.19 .09 .11 .10 .07 -.01 -.07 <.001 
Marital Status  -.10 -.11 -.14 .08 .04 .14 -.05 -.13 -.04 .04 -.20 -.15 -.18 -.23* -.31** .14 .21 -.03 
Income -.25** -.11 -.28** .15* .02 .03 -.21* -.23* -.25** .19* -.10 -.27 -.30**  -.22 -.34** .29* .37 .02 
Years of 
Education -.07 -.05 -.02 .20
* .05 .004 -.01 .04 -.02 .22* -.48* -.44* -.15 -.16 -.04 .22 -.37 -.26 
Cancer Type .13 .05 .16* -.18* .10 .09 .12 .10 -.01 -.12 -.24 -.09 .28* .25* .36** -.33** .16 .30 
Cancer Stage -.004 .01 .05 -.11 .10 .19 .09 -.02 .07 -.07 -.20 -.08 .31** .24* .29* -.34** .39 .70* 
Chemotherapy -.03 .08 -.02 -.05 .11 .10 -.11 -.15 -.16 .16 .09 .07 .21 .14 .16 -.17 .16 .63* 
Radiation -.07 -.06 .04 -.01 -.01 -.05 -.16 -.07 .04 .02 .33 .29 -.01 -.12 -.08 -.05 .34 -.12 
Surgery -.06 .01 -.004 .07 -.08 -.001 .17 .13 .16 -.03 .23 .24 .01 .03 .05 -.07 .21 .16 
Years Since 
Diagnosis -.06 -.001 -.07 .07 -.14 -.13 -.004 .06 -.05 .07 -.01 .05 -.09 -.12 -.05 .05 -.08 -.19 
IH variables                   
IH usage .18* .14 .01 -.01 .03 -.02 .01 -.002 .03 .05 -.18 -.14 -.003 -.03 -.10 .06 .38 .32 
Community  -.14 -.12 -.18 .17 .04 .06 -.02 .02 -.02 .12 -.40 -.19 -.05 -.04 .15 .08 <.001 -.08 









































































n 175 168 174 174 42 46 123 123 121 123 23 29 80 80 80 80 15 16 
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Table A-4.   
Factors associated with IH usage  
 Model 1: Depression (PHQ-9) 
 Est. (SE) OR (βe) CI- lower CI- upper p 
Gender -0.08 (.62) .93 0.27 3.12 .90 
Age -0.001 (.02) 1.00 0.97 1.03 .97 
Ethnicity 0.85 (.86) 2.34 0.43 12.6 .32 
Marital Status  -0.57 (.48) 0.57 0.22 1.44 .23 
Income -0.45 (.47) 0.64 0.26 1.59 .33 
Years of Education 0.04 (.05) 1.04 0.94 1.14 .44 
Cancer Type -0.42 (.47) 0.66 0.26 1.65 .37 
Chemotherapy 0.14 (.44) 1.15 0.48 2.75 .75 
Radiation -0.79 (.43) 0.45 0.20 1.05 .07 
Surgery -0.51 (.45) 0.60 0.25 1.44 .25 
Years Since Diagnosis -0.01 (.04) 0.99 0.92 1.06 .70 
Baseline PHQ-9 0.09 (.03) 1.10 1.03 1.17 .004** 
 Model 2: Anxiety (GAD-7) 
 Est. (SE) OR (βe) CI- lower CI- upper p 
Gender .13 (.64) 1.14 0.32 4.00 .84 
Age -0.001 (.02) 1.00 0.97 1.03 .94 
Ethnicity .90 (.86) 2.45 0.46 13.10 .30 
Marital Status  -0.60 (.49) 0.55 0.21 1.42 .22 
Income -0.27 (.46) 0.76 0.31 1.87 .56 
Years of Education .03 (.05) 1.03 0.93 1.13 .57 
Cancer Type -0.44 (.48) 0.64 0.25 1.65 .36 
Chemotherapy .34 (.45) 1.41 0.58 3.42 .45 
Radiation -0.69 (.44) 0.50 0.21 1.18 .11 
Surgery -0.40 (.45) 0.67 0.28 1.63 .38 
Years Since Diagnosis -0.03 (.04) 0.98 0.91 1.05 .51 
Baseline GAD-7 .09 (.03) 1.09 1.02 1.16 .01** 
 Model 3: Somatic Symptoms (PHQ-15) 
 Est. (SE) OR (βe) CI- lower CI- upper p 
Gender 0.07 (.60) 1.07 .33 3.49 .91 
Age -0.01 (.02) .99 .96 1.03 .65 
Ethnicity 1.09 (.84) 2.98 .58 15.35 .19 
Marital Status  -0.49 (.46) .61 .25 1.51 .29 
Income -0.16 (.45) .85 .35 2.05 .72 
Years of Education 0.03 (.05) 1.03 .94 1.13 .59 
Cancer Type -0.44 (.47) .65 .26 1.61 .35 
Chemotherapy 0.23 (.42) 1.25 .55 2.87 .59 
Radiation -0.58 (.41) .56 .25 1.24 .15 
Surgery -0.45 (.44) .64 .27 1.50 .31 
Years Since Diagnosis -0.01 (.03) .99 .92 1.06 .72 








Model 4: Health-Related Quality of Life (HRQOL) 
 Est. (SE) OR (βe) CI- lower CI- upper p 
Gender 0.15 (.61) 1.16 0.35 3.82 .81 
Age -0.01 (.02) 0.99 0.96 1.03 .61 
Ethnicity 1.09 (.84) 2.95 0.57 15.27 .20 
Marital Status -0.42 (.46) 0.65 0.26 1.62 .36 
Income -0.12 (.44) 0.89 0.38 2.11 .79 
Years of Education 0.03 (.05) 1.03 0.93 1.13 .61 
Cancer Type -0.38 (.46) 0.68 0.28 1.70 .41 
Chemotherapy 0.19 (.42) 1.21 0.53 2.78 .65 
Radiation -0.64 (.41) 0.53 0.24 1.18 .12 
Surgery -0.42 (.44) 0.66 0.28 1.55 .34 
Years Since Diagnosis -0.02 (.04) 0.98 0.91 1.05 .54 
Baseline HRQOL 0.02 (.18) 1.02 0.72 1.44 .92 
Note. *p < .05; **p < .01;   
           IH usage (1 = Yes; 0 = No) reflects overall use (i.e., usage at most recent time point); 
           Due to a high degree of correlation between cancer variables (i.e., cancer type, cancer 












Table A-5.  
Outcomes data for IH usage at 3-month follow-up 
 Model 1a: Depression (PHQ-9); R2 = .38 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 
-1.40 (.81) -0.13 -3.01 0.21 .09 
Baseline PHQ-9 0.53 (.06) 0.63 0.41 0.66 .000** 
 Model 1b: Depression (PHQ-9); R2 = .37 
 Est. (SE) β CI- lower CI- upper p 
IH dosage 
(minutes) 
-0.003 (.003) -0.07 -0.01 0.003 .34 
Baseline PHQ-9 0.52 (.06) 0.62 0.40 0.64 .000** 
 Dep (T1) Dep (T2) n   
M (SD) 7.66 (6.4) 5.73 (5.4) 122   
 Model 2a: Anxiety (GAD-7); R2 = .37 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 
-0.48 (.74) -0.05 -1.94 0.98 .52 
Baseline GAD-7 0.50 (.06) 0.62 0.39 0.62 .000** 
 Model 2b: Anxiety (GAD-7); R2 = .37 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) 
-0.002 (.003) -0.06 -0.01 0.003 .41 
Baseline GAD-7 0.51 (.06) 0.63 0.39 0.63 .000** 
 Anx (T1) Anx (T2) n   
M (SD) 5.84 (5.9) 4.47 (4.8) 118   
 Model 3a: Somatic Symptoms (PHQ-15); R2 = .49 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 
-0.17 (0.64) -0.02 -1.44 1.11 .80 
Baseline PHQ-15 0.64 (0.06) 0.70 0.52 0.76 .000** 
 Model 3b: Somatic Symptoms (PHQ-15); R2 = .48 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) 
0.000 (.002) 0.01 -0.01 .005 .93 
Baseline PHQ-15 0.64 (.06) 0.70 0.52 0.76 .000** 
 Som (T1) Som (T2) n   
M (SD) 8.65 (5.2) 7.57 (4.7) 119   
 Model 4a: Health-Related Quality of Life (HRQOL); R2 = .48 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 
0.32 (.15) 0.14 0.03 0.62 .03* 
Baseline HRQOL 0.70 (.07) 0.70 0.57 0.83 <.001** 
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 Model 4b: Health-Related Quality of Life (HRQOL); R2 = .47 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) 
0.001 (.001) 0.07 -0.001 0.002 .30 
Baseline HRQOL 0.69 (.07) 0.69 0.56 0.82 <.001** 
 QoL (T1) QoL (T2) n   
M (SD) 3.10 (1.1) 3.02 (1.1) 122   
 Model 5a: C-Reactive Protein (CRP); R2 = .35 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 
-0.32 (.32) -0.19 -0.99 0.34 .32 
Baseline CRP 0.83 (.25) 0.61 0.30 1.36 .004** 
 Model 5b: C-Reactive Protein (CRP); R2 = .33 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) 
-0.001 (.001) -0.13 -0.004 0.002 .50 
Baseline CRP 0.83 (.26) 0.61 0.29 1.37 .01** 
 CRP (T1) CRP (T2) n   
M (SD) 0.53 (0.6) 0.62 (0.8) 20   
 Model 6a: Interleukin-6 (IL-6); R2 = .55 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 
-1.25 (1.1) -0.15 -3.60 1.09 .28 
Baseline IL-6 0.68 (.12) 0.75 0.43 0.94 .000** 
 Model 6b: Interleukin-6 (IL-6); R2 = .56 
 Est. (SE) β   CI- lower CI- upper p 
IH dosage  
(minutes) 
-0.01 (.01) -0.18 -0.02 0.003 .20 
Baseline IL-6 0.68 (.12) 0.74 0.43 0.93 .000** 
 IL-6 (T1) IL-6 (T2) n   
M (SD) 4.14 (4.6) 4.07 (4.2) 26   







Table A-6.  
Outcomes data for IH usage at 3-month follow-up, controlling for community 
usage (subset only) 
 Model 1a: Depression (PHQ-9); R2 = .32 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 
-0.87 (1.0) -0.08 -2.90 1.15 .39 
Baseline PHQ-9 0.54 (.09) 0.61 0.36 0.71 .00** 
Community usage 0.88 (1.1) 0.08 -1.22 2.97 .41 
 Model 1b: Depression (PHQ-9); R2 = .31 
 Est. (SE) β CI- lower CI- upper p 
IH dosage 
(minutes) 
-0.002 (.004) -0.05 -0.01 0.01 .62 
Baseline PHQ-9 0.53 (.09) 0.59 0.35 0.70 .00** 
Community usage 0.74 (1.0) 0.07 -1.33 2.82 .48 
 Dep (T1) Dep (T2) n   
M (SD) 7.10 (5.9) 5.56 (5.2) 77   
 Model 2a: Anxiety (GAD-7); R2 = .32 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 
-0.56 (.84) -0.07 -2.24 1.12 .51 
Baseline GAD-7 0.51 (.08) 0.60 0.34 0.68 .00** 
Community usage 1.60 (.91) 0.18 -0.22 3.42 .09 
 Model 2b: Anxiety (GAD-7); R2 = .32 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) 
-0.002 (.003) -0.08 -0.01 0.004 .43 
Baseline GAD-7 0.51 (.08) 0.60 0.34 0.67 .00** 
Community usage 1.54 (.90) 0.17 -0.25 3.33 .09 
 Anx (T1) Anx (T2) n   
M (SD) 5.12 (5.1) 4.00 (4.3) 74   
 Model 3a: Somatic Symptoms (PHQ-15); R2 = .53 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 
-0.31 (0.75) -0.03 -1.80 1.19 .69 
Baseline PHQ-15 0.69 (0.07) 0.75 0.54 0.83 .00** 
Community usage 1.02 (0.79) 0.11 -0.56 2.60 .20 
 Model 3b: Somatic Symptoms (PHQ-15); R2 = .53 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) 
-0.002 (.003) -0.05 -0.01 .004 .52 
Baseline PHQ-15 0.68 (.07) 0.75 0.53 0.83 .00** 
Community usage 0.99 (.78) 0.10 -0.57 2.54 .21 
 Som (T1) Som (T2) n   
M (SD) 8.49 (5.1) 7.60 (4.6) 75   
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 Model 4a: Health-Related Quality of Life (HRQOL); R2 = .42 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 
0.43 (.19) 0.20 0.05 0.82 .03* 
Baseline HRQOL 0.65 (.09) 0.66 0.47 0.82 <.001** 
Community usage -0.03 (.21) -0.01 -0.44 0.38 .89 
 Model 4b: Health-Related Quality of Life (HRQOL); R2 = .38 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) 
0.00 (.001) 0.04 -0.001 0.002 .70 
Baseline HRQOL 0.62 (.09) 0.64 0.44 0.80 <.001** 
Community usage 0.05 (.21) 0.02 -0.36 0.47 .81 
 QoL (T1) QoL (T2) n   
M (SD) 3.16 (1.1) 3.05 (1.1) 76   
 Model 5a: C-Reactive Protein (CRP); R2 = .38 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 
-0.19 (.71) -0.09 -2.02 1.63 .80 
Baseline CRP 1.07 (.60) 0.56 -0.46 2.61 .13 
Community usage -1.02 (.68) -0.43 -2.76 0.72 .19 
 Model 5b: C-Reactive Protein (CRP); R2 = .38 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) 
-0.001 (.002) -0.08 -0.01 0.01 .81 
Baseline CRP 1.09 (.57) 0.57 -0.38 2.56 .12 
Community usage -1.05 (.67) -0.44 -2.78 0.68 .18 
 CRP (T1) CRP (T2) n   
M (SD) 0.57 (0.6) 0.76 (1.2) 9   
 Model 6a: Interleukin-6 (IL-6); R2 = .63 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 
-1.48 (1.7) -0.16 -5.27 2.31 .40 
Baseline IL-6 0.88 (.20) 0.78 0.43 1.33 .001** 
Community usage -1.68 (1.6) -0.17 -5.32 1.95 .33 
 Model 6b: Interleukin-6 (IL-6); R2 = .63 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) 
-0.01 (.01) -0.14 -0.02 0.01 .43 
Baseline IL-6 0.90 (.20) 0.79 0.46 1.34 .001** 
Community usage -1.83 (1.6) -0.19 -5.50 1.83 .29 
 IL-6 (T1) IL-6 (T2) n   
M (SD) 3.92 (4.4) 3.87 (5.0) 14   




Table A-7.  
Outcomes data for Composite usage (IH usage + Community usage) at 3-month 
follow-up (subset only)  
 Model 1: Depression (PHQ-9); R2 = .32 
 Est. (SE) β CI- lower CI- upper p 
Composite usage   
(0=No; 1=Yes) 
0.19 (1.0) 0.02 -1.80 2.19 .85 
Baseline PHQ-9 0.51 (.08) 0.58 0.34 0.68 .000** 
 Dep (T1) Dep (T2) n   
M (SD) 7.10 (5.9) 5.56 (5.2) 77   
 Model 2: Anxiety (GAD-7); R2 = .31 
 Est. (SE) β CI- lower CI- upper p 
Composite usage   
(0=No; 1=Yes) 
1.04 (.84) 0.12 -0.64 2.71 .22 
Baseline GAD-7 0.48 (.08) 0.57 0.31 0.64 <.001** 
 Anx (T1) Anx (T2) n   
M (SD) 5.12 (5.1) 4.00 (4.3) 74   
 Model 3: Somatic Symptoms (PHQ-15); R2 = .53 
 Est. (SE) β CI- lower CI- upper p 
Composite usage   
(0=No; 1=Yes) 
0.16 (0.76) 0.02 -1.35 1.67 .83 
Baseline PHQ-15 0.67 (0.07) 0.73 0.52 0.81 .000** 
 Som (T1) Som (T2) n   
M (SD) 8.49 (5.1) 7.60 (4.6) 75   
 Model 4: Health-Related Quality of Life (HRQOL); R2 = .40 
 Est. (SE) β CI- lower CI- upper p 
Composite usage   
(0=No; 1=Yes) 
0.17 (.20) 0.08 -0.23 0.56 .41 
Baseline HRQOL 0.63 (.09) 0.64 0.45 0.81 <.001** 
 QoL (T1) QoL (T2) n   
M (SD) 3.16 (1.1) 3.05 (1.1) 76   
 Model 5: C-Reactive Protein (CRP); R2 = .65 
 Est. (SE) β CI- lower CI- upper p 
Composite usage   
(0=No; 1=Yes) 
-1.60 (.60) -0.59 -3.07 -0.13 .04* 
Baseline CRP 0.90 (.42) 0.47 -0.14 1.94 .08 
 CRP (T1) CRP (T2) n   
M (SD) 0.57 (0.6) 0.76 (1.2) 9   
 Model 6: Interleukin-6 (IL-6); R2 = .74 
 Est. (SE) β CI- lower CI- upper p 
Composite usage   
(0=No; 1=Yes) 
-3.61 (1.5) -0.34 -6.93 -0.28 .04* 
Baseline IL-6 0.88 (.16) 0.78 0.53 1.24 .000** 
 IL-6 (T1) IL-6 (T2) n   
M (SD) 3.92 (4.4) 3.87 (5.0) 14   





Table A-8.  
One-way ANOVA of Outcome Mean Change Scores (T2-T1) by IH Service 
 Service Type    
 Massage therapy  Psychotherapy Acupuncture F p η2 
Outcomes n M (SE) n M (SE) n M (SE)    
Depression 
(T2-T1) 
20 -1.65 (.73) 14 -7.71 (2.0) 10 -1.50 (.78) 4.93 .005** .265 
Anxiety 
(T2-T1) 




20 -0.65 (.87) 14 -3.14 (1.1) 10 -0.40 (1.3) 1.67 .188 .109 
HRQOL 
(T2-T1) 
20  0.05 (.17) 14 0.21 (.33) 10  0.30 (.30) .175 .913 .013 














































Table A-9.  
Independent T-test of Outcome Mean Change Scores (T2-T1) by IH usage 
 IH usage    
 Yes  No t p η2 
Outcomes n M (SE) n M (SE)    
Depression 
(T2-T1) 
45 -3.58 (.83) 77 -0.97 (.56) 2.70 .008** .057 
Anxiety 
(T2-T1) 




45 -1.29 (.62) 74 -0.95 (.42) 0.47 .638 .002 
HRQOL 
(T2-T1) 























Table A-10.  
Independent T-test of Outcome Mean Change Scores (T2-T1) by Self-Reported 
Community usage.   
 Community usage    
 Yes  No t p η2 







-1.30 .197 .022 
Anxiety 
(T2-T1) 
24 0.58 (.87) 50 -1.94 
(.61) 




26 0.77 (.62) 49 -1.41 
(.53) 
-1.73 .087 .039 
HRQOL 
(T2-T1) 




0.33 .746 .001 
        Note. *p < .05; **p < .01 
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Table A-11.  
Outcomes data for IH usage at 12-month follow-up 
 Model 1a: Depression (PHQ-9); R2 = .51 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) -1.73 (1.2) -0.12 -4.12 0.66 .15 
Baseline PHQ-9 0.73 (.08) 0.73 0.57 0.88 <.001** 
 Model 1b: Depression (PHQ-9); R2 = .51 
 Est. (SE) β CI- lower CI- upper p 
IH dosage 
(minutes) -0.003 (.002) -0.10 -0.01 0.001 .19 
Baseline PHQ-9 0.72 (.08) 0.72 0.56 0.87 <.001** 
 Dep (T1) Dep (T2) n   
M (SD) 7.84 (6.6) 6.72 (6.6) 79   
 Model 2a: Anxiety (GAD-7); R2 = .36 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) -1.80 (1.2) -0.14 -4.14 0.55 .13 
Baseline GAD-7 0.53 (.08) 0.62 0.37 0.69 <.001** 
 Model 2b: Anxiety (GAD-7); R2 = .37 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) -0.004 (.002) -0.16 -0.01 0.001 .09 
Baseline GAD-7 0.52 (.08) 0.62 0.37 0.68 <.001** 
 Anx (T1) Anx (T2) n   
M (SD) 6.80 (6.3) 5.01 (5.4) 76   
 Model 3a: Somatic Symptoms (PHQ-15); R2 = .47 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) -1.09 (1.1) -0.08 -3.25 1.07 .32 
Baseline PHQ-15 0.73 (0.09) 0.69 0.55 0.91 <.001** 
 Model 3b: Somatic Symptoms (PHQ-15); R2 = .47 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) -0.001 (.002) -0.04 -0.01 .003 .66 
Baseline PHQ-15 0.73 (.09) 0.69 0.55 0.91 <.001** 
 Som (T1) Som (T2) n   
M (SD) 9.05 (5.4) 7.71 (5.7) 78   
 Model 4a: Health-Related Quality of Life (HRQOL); R2 = .42 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 0.02 (.22) 0.01 -0.41 0.45 .93 
Baseline HRQOL 0.68 (.09) 0.66 0.50 0.85 <.001** 
  




Table A-11 Continued  
 
 Model 4b: Health-Related Quality of Life (HRQOL); R2 = .43 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) .000 (.000) 0.07 .000 .001 .44 
Baseline HRQOL 0.67 (.09) 0.65 0.49 0.84 <.001** 
 QoL (T1) QoL (T2) n   
M (SD) 3.12 (1.1) 3.11 (1.1) 79   
 Model 5a: C-Reactive Protein (CRP); R2 = .17 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) 0.09 (.15) 0.17 -0.24 0.43 .56 
Baseline CRP 0.19 (.12) 0.45 0.07 0.45 .14 
 Model 5b: C-Reactive Protein (CRP); R2 = .24 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) -0.001 (.001) -0.35 -0.002 0.001 .26 
Baseline CRP 0.30 (.12) 0.72 0.03 0.57 .03* 
 CRP (T1) CRP (T2) n   
M (SD) 0.63 (0.6) 0.31 (0.3) 14   
 Model 6a: Interleukin-6 (IL-6); R2 = .54 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) -1.59 (2.5) -0.15 -6.99 3.81 .53 
Baseline IL-6 0.78 (.23) 0.81 0.28 1.27 .01** 
 Model 6b: Interleukin-6 (IL-6); R2 = .68 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) -0.02 (.01) -0.58 -0.04 -0.007 .01
** 
Baseline IL-6 1.04 (.19) 1.08 0.64 1.45 .000** 
 IL-6 (T1) IL-6 (T2) n   
M (SD) 4.63 (5.3) 5.07 (5.1) 15   







Table A-12.  
Outcomes data for IH usage at 12-month follow-up, controlling for community 
usage (subset only)  
 Model 1a: Depression (PHQ-9) ); R2 = .48 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) -1.31 (1.8) -0.10 -4.95 2.32 .47 
Baseline PHQ-9 0.84 (.14) 0.74 0.55 1.13 <.001** 
Community usage 0.69 (1.7) 0.05 -2.67 4.05 .68 
 Model 1b: Depression (PHQ-9); R2 = .47 
 Est. (SE) β CI- lower CI- upper p 
IH dosage 
(minutes) .000 (.004) 0.01 -0.01 0.01 .93 
Baseline PHQ-9 0.82 (.14) 0.72 0.53 1.10 <.001** 
Community usage 0.22 (1.7) 0.02 -3.30 3.75 .90 
 Dep (T1) Dep (T2) n   
M (SD) 6.14 (5.5) 5.44 (6.2) 36   
 Model 2a: Anxiety (GAD-7); R2 = .20 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) -2.13 (1.5) -0.24 -5.08 0.83 .15 
Baseline GAD-7 0.43 (.13) 0.51 0.16 0.71 .003** 
Community usage 1.40 (1.4) 0.17 -1.45 4.24 .33 
 Model 2b: Anxiety (GAD-7); R2 = .16 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) -0.003 (.004) -0.12 -0.01 0.005 .47 
Baseline GAD-7 0.41 (.14) 0.48 0.13 0.68 .01** 
Community usage 1.14 (1.47) 0.14 -1.86 4.14 .44 
 Anx (T1) Anx (T2) n   
M (SD) 5.22 (4.8) 3.58 (4.1) 36   
 Model 3a: Somatic Symptoms (PHQ-15); R2 = .48 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) -2.13 (1.6) -0.17 -5.36 1.10 .19 
Baseline PHQ-15 0.78 (.14) 0.69 0.49 1.06 .000** 
Community usage 2.04 (1.5) 0.18 -0.97 5.04 .18 
 Model 3b: Somatic Symptoms (PHQ-15); R2 = .46 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) -0.003 (.004) -0.09 -0.01 .01 .51 
Baseline PHQ-15 0.77 (.14) 0.68 0.49 1.06 <.001** 
Community usage 1.87 (1.6) 0.16 -1.35 5.09 .25 
 Som (T1) Som (T2) n   






















Table A-12 Continued 
 
 Model 4a: Health-Related Quality of Life (HRQOL); R2 = .41 
 Est. (SE) β CI- lower CI- upper p 
IH usage  
(0=No; 1=Yes) -0.06 (.34) -0.25 -0.75 0.62 .86 
Baseline HRQOL 0.71 (.14) 0.68 0.43 0.98 <.001** 
Community usage 0.10 (.31) 0.04 -0.54 0.74 .75 
 Model 4b: Health-Related Quality of Life (HRQOL); R2 = .42 
 Est. (SE) β CI- lower CI- upper p 
IH dosage  
(minutes) .000 (.001) 0.08 -0.001 0.002 .61 
Baseline HRQOL 0.69 (.14) 0.66 0.41 0.97 <.001** 
Community usage 0.01 (.33) 0.01 -0.65 0.68 .97 
 QoL (T1) QoL (T2) n   





























Table A-13.  
Outcomes data for Composite usage (IH usage + Community usage) at 12-month 
follow-up (subset only) 
 Model 1: Depression (PHQ-9); R2 = .49 
 Est. (SE) β CI- lower CI- upper p 
Composite usage   
(0=No; 1=Yes) -0.18 (1.5) -0.02 -3.21 2.85 .91 
Baseline PHQ-9 0.82 (.14) 0.72 0.54 1.10 <.001** 
 Dep (T1) Dep (T2) n   
M (SD) 6.14 (5.5) 5.44 (6.2) 36   
 Model 2: Anxiety (GAD-7); R2 = .17 
 Est. (SE) β CI- lower CI- upper p 
Composite usage   
(0=No; 1=Yes) -0.09 (1.26) -0.01 -2.65 2.46 .94 
Baseline GAD-7 0.39 (.13) 0.46 0.12 0.66 .01** 
 Anx (T1) Anx (T2) n   
M (SD) 5.22 (4.8) 3.58 (4.1) 36   
 Model 3: Somatic Symptoms (PHQ-15); R2 = .45 
 Est. (SE) β CI- lower CI- upper p 
Composite usage   
(0=No; 1=Yes) 0.14 (1.40) 0.001 -2.84 2.87 .99 
Baseline PHQ-15 0.78 (0.14) 0.69 0.49 1.07 <.001** 
 Som (T1) Som (T2) n   
M (SD) 8.33 (5.0) 6.78 (5.6) 36   
 Model 4: Health-Related Quality of Life (HRQOL); R2 = .43 
 Est. (SE) β CI- lower CI- upper p 
Composite usage   
(0=No; 1=Yes) -0.16 (.28) -0.07 -0.73 0.41 .57 
Baseline HRQOL 0.71 (.13) 0.68 0.44 0.98 <.001** 
 QoL (T1) QoL (T2) n   
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